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                                1. INTRODUCTION 
  The oral route of drug administration is the important method of 
administering drug for systemic effects. Except in certain cases the parentral route is 
not routinely used for self administration e.g. insulin. The topical route of 
administration has only recently been developed to deliver drugs to the body for 
systemic effect. The parentral route of administration is important in treating medical 
emergencies in which the subject is coma or unable to swallow. Nevertheless at least 
90% of all drugs used to provide systemic effect are administered by oral route. When 
a new drug is developed pharmaceutical company ask is whether or not the drug can 
be  effectively administered for its intended effect by oral route of drug that are 
administered orally, solid oral dosage forms indicates the preferred class of product. 
Tablet and capsules indicates unit dosage forms in which usual dose of drug has been 
accurately placed1. 
 Tablet is defined as solid pharmaceutical dosage form containing drug 
substance with or with out suitable excipients  and prepared by either compression or 
molding method. They have been widely used since the later part of the 19th century, 
and their popularity continues. The term compressed tablet is believed to have been 
used by wyeth and brother of Philadelphia. During this same period, molded tablet 
were introduced to use as hypodermic tablets for the preparation of solution for 
injection. Tablet remains popular as a dosage form because of the advantages both to 
the manufacturer (e.g. simplicity and economy of preparation, stability, and 
convenience in packing, shipping and dispensing) and patient (e.g. accuracy of 
dosage, compactness, portability, blandness of taste, and ease of administration). 
Although the basic medicinal approach for their manufacture has remained the same, 
tablet technology has gained great improvement. Effect are being made continually to 
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understand more clearly the physical characteristics of powder compaction and the 
factor affecting the bioava
administration1,2. 
 Although tablets frequently are discoid in shape, they 
round, oval oblong, cylinder or triangular
and weight depending on the amount of the drug substance present and the intended 
method of administration. They are divided into two classes by whet
by compression or molding. Compressed 
production method, while molded tablets generally involve small
method. Tablet formulation and design may described as the process where 
formulator ensures that the current amount of the drug in the right form is delivered at 
or over the proper time at the proper rate and in the desired location, while having its 
chemical integrity protected to that point. Most recently, new concept and
regulations being made on bioavailability and bioequivalence and on validation are 
influencing on tablet formulation, design and manufacture
 
 
 
 
 
 
 
Fig No.1: Relationship between drug concentration or activity and time, for products 
possessing various release profiles. A, immediate release; B, Delayed action; C, 
Repeat action; D, Prolonged release; E, controlled; sustained release.
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1.1 Types of tablets1 
• Compressed tablet 
• Multi compressed tablet  
 Layered tablet  
 Compression coated tablet 
• Repeat action tablet 
• Delayed action and Enteric coated tablet 
• Sugar coated tablets 
• Chewable tablets 
• Buccal tablets   
• Sublingual tablets 
• Troches and Lozenges  
• Dental cones  
• Implantation tablets 
• Vaginal tablets  
• Effervescent tablets 
• Dispersible tablets 
• Hypodermic tablets 
  
Tablets used in the Oral Cavity
 
The tablets under this group are aimed release API in oral cavity or to provide 
local action in this region. They avoids first-pass metabolism, decomposition in 
gastric environment, nauseatic sensations and gives rapid onset of action. The tablets 
formulated for this region are designed to fit in proper region of oral cavity.  
a) Lozenges and troches 
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b) Sublingual tablet 
c) Buccal tablet 
d) Dental cones 
e) Mouth dissolved tablet 
 
Tablets Administered by Other Routes 
 
These tablets are administered by other route except for the oral cavity and so 
the drugs are avoided from passing through gastro intestinal tract. These tablets may 
be inserted into other body cavities or directly placed below the skin to be absorbed 
into systemic circulation from the site of application.  
 
a) Vaginal tablet 
b) Implants 
 
Tablets used to prepare Solution 
 
The tablets under this category are required to be dissolved first in water or 
other solvents before administration or application. This solution may be for ingestion 
or parenteral application or for topical use depending upon type of medicament used. 
a) Effervescent tablet 
b) Hypodermic tablet 
c) Soluble tablet 
 
1.2 Tablet Properties 
Tablets can be made in any shape, although requirements of patients and 
tableting machines mean that most are round, oval or capsule shaped. More unusual 
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shapes have been manufactured but patients find these difficult to swallow, and they 
have more manufacturing problems. 
Tablet diameter, size  and shape are determined by the machine tooling used to 
produce them - a die cavity,  upper and a lower punch were required. This is called an 
station of tooling. The thickness is determined by the amount of tablet material and 
the position of the punches used during compression. Once this is done, we can 
measure the corresponding pressure applied during compression. The shorter the 
distance between the punches, thickness, and the greater the pressure applied during 
compression and the harder the tablet. Tablets need to be hard enough that they don't 
break up in the bottle, friable enough that they disintegrate in the gastric medium. 
The tablet is composed of the Active Pharmaceutical Ingredient (active drug) 
and with various excipients. These are biologically inert ingredients which enhance 
the therapeutic effect or are necessary to design the tablet. The filler or diluents (e.g. 
Lactose, mannitol or  Sorbitol) were  bulking agents, providing a quantity of material 
which can accurately be formed into a tablet. Binders (e.g. methyl cellulose,starch or 
gelatin) hold the ingredients together so that they can form a tablet. Lubricants (e.g. 
magnesium stearate, talc or polyethylene glycol) were added to reduce the friction 
between the tablet, punches and dies so that the tablet compression and ejection 
processes are in smooth. Disintegrants or superdisintegrants (e.g. starch or cellulose) 
are used to promote wetting and swelling of the tablet so that it breaks up in the 
gastrointestinal medium; this is necessary for the dissolution of API. 
Superdisintegrants are sometimes used to increase the speed of disintegration of 
tablet. Additional ingredients may also be added such as coloring agents, flavoring 
agents and coating agents for the development of tablet. Formulations which are 
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designed using small quantities in a laboratory machine called as Powder Compaction 
Simulator machine3.  
 
1.3 Choice of Excipients 
The selection of excipients in tablet formulations depends on the API, the type 
of tablet, the desired characteristics, and the manufacturing process used. Several 
types of tablets were available in the market. They include prompt release, from 
which the drug dissolves in a very short time (sublingual or buccal tablets), and 
immediate release and modified release, which includes most of the oral administered 
tablets that were swallowed. Other types include effervescent, bilayered, chewable, 
multiple compressed tablets and tablets for solution. The particular characteristics of a 
tablet may be achieved by adding colors, pigments, flavours, sweeteners and a sugar 
or film coating. The types of excipients selected for a formulation depend on the basic 
process used to manufacture the tablets4.  
 
1.4 Drug-Excipient Interactions and Their Effect on Absorption  
Excipients were traditionally used  as an inert substances but they can have 
tremendous impact on the pharmacological activity of a drug substance when added to 
a formulation. The effect will depend on the characteristics of the drug and on the 
quantity and properties of the excipients used. Excipients were classified according to 
the formulation, although many excipients perform multiple functions. Diluents allow 
the formulation of a tablet and can form large proportion by weight of a formulated 
product when the active ingredient is very potent. The physical characteristics of the 
diluents play an important role; for example, triamterene was shown to dissolve more 
rapidly when it was formulated with hydrophilic fillers such as lactose and starch as 
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compared with insoluble diluents. Disintegrants swell when wetted and  are added to a 
formulation to facilitate the breakdown of the dosage form into granules and powder 
particles. The newer disintegrants, called superdisintegrants, provides an extremely 
rapid break up of a tablet owing to their ability to swell to many times of their original 
size. Wicking and swelling were primary mechanisms of actions for tablet 
disintegrants, while other mechanisms, such as deformation recovery, particle 
repulsion theory, heat of wetting and evolution of a gas etc., may play a role in tablet 
disintegration. Co processing is defined as combining or more established excipients 
by an appropriate. Coprocessing of excipient could lead to formation of excipients 
with major properties compared with the simple physical mixtures of their   
components or with individual components. A large number of coprocessed diluents 
are commercially used. The representative examples are Ludipress, Cellactose and 
starlac. The use of co-processing is totally unexplored avenues in disintegrants. The 
widely used super disintegrants are Sodium Starch Glycolate, crospovidone and 
croscaramellose sodium were used as super disintegrants have strengths and 
weakness.  
 
1.5 Excipients used in tablets 
Excipients are inert substances used as diluents or vehicles for a drug. Various 
diluents or fillers, binders or adhesives, disintegrates, lubricants, glidants or flavours, 
fragrances and sweeteners were used as excipients. 
They must meet certain criteria as follows  
• They must be physiological inert substances. 
• They must be acceptable to regulatory authorities. 
• They must have physic chemical stability 
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• They must be free of micro organisms considered to be harmfull or otherwise 
objectionable. 
• They should not be interfering with the bioavailability of the drug. 
• They must be commercially available and should have purity according to 
pharmaceutical standards. 
• Cost must be inexpensive. 
• They should meet all current regulatory requirements. 
• To assure that no excipient interferences with the utilization of the drug, the 
formulator must carefully and critically evaluate combinations of the drug 
with each of the excipients and must consider compliance of each ingredient 
with existing standards and regulatory requirements. 
• The drug-excipients and excipient-excipient interactions should be carried out 
in preformulations studies. 
 
1.5.1 Fillers 
Fillers are comprise a heterogeneous group of substances. Since they often 
forms the bulk of the tablet, selection of a candidate from this group as a carrier for a 
drug is of primary importance. 
Eg: lactose,  mannitol,  dicalcium phosphate anhydrous. 
 
1.5.2 Binders 
Binders are the adhesives that holds powders together to form granules. They 
are the adhesives that are added to tablet formulations to provide the cohesiveness 
required for that bonding together for the granules under compaction to form  tablet. 
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The quantity used and the method of using must be carefully regulated, since the 
tablet must remain intact when swallowing and then release its medicaments. 
Binders are either sugar or polymeric materials the latter fall into two classes 
Natural polymers such as starches or gums include acacia, tragacanth and gelatin. 
Synthetic polymers such as PVP methyl cellulose and ethyl cellulose and hydroxyl 
propyl methyl cellulose. Binders of  both types may be added to the powder mix and 
the mixture wetted with water, alcohol–water mixtures are also used as solvent, or 
binder may be put into solution in the water, solvent and added to the powder. The 
other method using the solution of the binder requires much less binding material to 
achieve the same hardness than if added dry.Mostly used binders are gelatin, glucose, 
methyl cellulose, acacia, starch paste, povidone, alcohol, PVP in water, PVP in 
alcohol and sorbitol in water 
 
 
 
1.5.3 Lubricants 
Lubricants are used in tablet formulation for the ejection of the tablet from the 
die cavity, to prevent sticking of tablets to the punches, and to prevent excessive wear 
on punches and dies during compression. They function by interposing a film of low 
shear strength at the interface between the tablet and die cavity and the punch surface. 
Lubricants must be carefully selected for efficiency and for the properties of the tablet 
formulation. 
In selecting a lubricant, the following should be considered: 
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Lubricants reduce the bonding properties of many excipients. Over blending is 
one of the main causes of lubrication problems during the formulation. Lubricants 
should be added last to the granulation and blended for 10 min. 
Lubricant efficiency is a function of particle size; therefore, the finest grade 
available should be used and screened through a 100-300 mesh screen before use in 
formulation. 
Commonly used lubricants are magnesium stearate, talc, starch. 
 
1.5.4 Disintegrants 
Disintegrants are used in tablet preparation to break the tablet rapidly. But 
some of the disintegrants are also having property of enhancing solubility of insoluble 
dosage forms 
Examples 
Crospovidone: Crospovidone is disintegrant it also enhances solubility of drug. 
Sodium starch glycollate: sodium starch glycollate is widely used in oral 
pharmaceuticals and as a disintegrant in capsule formulation. 
Sodiumcrosscormellose  
1.5.5 Glidants 
Glidants are materials that are used to improve the flow characteristics of 
granules by reducing the inter particulate friction during processing in proper amounts 
they also serve to assure smooth and uniform flow of granules. 
 
1.5.6 Desired criteria for mouth dissolving drug delivery system 
Mouth dissolving tablet should 
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• Not require water to swallow, but it should dissolve or disintegrate in the 
mouth in matter of seconds. 
• Be compatible with taste masking. 
• Be portable without fragility concern. 
• Have a pleasing mouth feel. 
• Leave minimal or no residue in the mouth after oral administration. 
• Exhibit low sensitivity to environmental conditions as humidity and 
temperature. 
• Allows the manufacture of tablet using conventional processing and 
packaging equipment at low cost. 
The several advantages of fast dissolving dosage forms are  
1. Ease of administration for patients, those who are not co-operative. 
2. Quick disintegration and dissolution of the dosage form. 
3. Can be swallowed without water. 
4. Allows high drug loading. 
5. Can be designed to lave minimal or no residue in the mouth after 
administration and also provide a pleasant mouth feel. 
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1.6 Super disintegrants in immediate release tablets 
  A disintegrant were  added to a tablet or capsule blend to aid in the breakup of 
the compacted mass when it is put into a fluid medium. This is especially important 
for immediate release products where rapid release of drug substance is required. A 
disintegrant can be added to a powder mix for direct compression , wet granulation or 
encapsulation . While there are some tablets fillers such as starch microcrystalline 
cellulose which helps in disintegration, there are referred to as superdisintegrants. 
 
1.6.1 Method of Addition of Disintegrants  
  The requirement placed on the tablet disintegration should be clearly defined. 
The ideal disintegrant has, 
• Good solubility. 
• Poor gel formation.  
• Good hydration capacity. 
• Good molding and flowing properties.  
• No tendency to form complexes with other excipients. 
  Disintegrants are widely added to tablet granulation for the compressed tablet 
to break or disintegrate when placed in aqueous environment. 
 There are two methods of incorporating disintegrating agents into tablets: 
• Internal addition method 
• External addition method 
• Partly internal and external methods 
  In external addition method, the disintegrant is added to the sized granulation 
with mixing prior to compression. In internal addition method, the disintegrant is 
mixed with other powders before wetting the powder mixture with the granulating 
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fluid. Thus the disintegrant is incorporated within the granules. When these methods 
are used part of the disintegrants are added internally and part externally. This 
provides immediate dispersion of the tablet into previous compressed granules while 
the disintegrating agents within the granules produce further erosion of the granules to 
the original powder particles. The two stepped method usually produces better and 
more complete disintegration than the usual method of adding the disintegrant to the 
granulation surface only. 
 
1.7   Tablet processing 
 Pharmaceutical products are processed all over the world using the direct 
compressing, wet granulation, or dry granulation method. Method is chosen depend 
on the ingredients individual characteristics like flow property, compressibility. 
Choosing a method required through investigation of each ingredient in the formula, 
the combination of ingredients, and how they work with each other. Then the proper 
granulation process can applied. 
 
1.7.1 Direct compression1 
 Direct compression name implies compressing tablets directly from powdered 
materials without modifying the physical nature of the material itself. Direct 
compression is generally done for the crystalline material having good physical 
properties required for formulation of good tablets. Main advantage of direct 
compression is it saves time when compared to another method of compression like 
wet granulation. 
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Advantage: 
• Low labor in put 
• Drying process 
• Fewest processing steps 
Limitations: 
• Differences in densities and particle size cause stratification, which may lead 
to content uniformity problem of low dose drugs. 
• Large dose drugs which are not easily compressible by it could require an 
amount of diluents so large that the resultant tablet is costly and difficult to 
swallow (API usually restricted to 30% of a direct compressible formula). 
• Because of dry nature compression static charge build up can occur. 
 
1.7.2 Factors to be considered for directly compressible excipients: 
Flowability  
 Press speed requires powder to be very fluid, a property commonly referred to 
as product flow ability. Good flow characteristic are necessary because the 
mechanical action of the table press requires a volume of fill and this volume fill 
represent the actual tablet weight. Thus the powders in the formula must possess a 
consistent particle- size distribution and density to attain proper flow and achieve 
volume of fill. 
 
Compressibility  
 Compressing a tablet of different powder that have varying physical 
characteristic can be difficult. If the formula has some of both characteristics larger 
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particles with high moisture content and small, dry particles then the tablet may or 
may not compress well and probably will have difficulty holding together. 
 Directly compressible materials are preprocessed or found naturally in the 
granular state. The reduced number of processing steps required by directly 
compressible material allows for less equipment and shorter process time comparison 
with wet or dry granulation processes. 
 
 1.8 Wet granulation1,3  
 Mostly widely used and most general method of tablet preparation is by wet 
granulation method. Wet granulation forms the granules by binding the powders 
together with an adhesion instead of by compaction. The wet granulation technique is 
done by adding a solute, suspension or slurry containing binder this can be aqueous or 
non aqueous which is added to the dry mix powder. The surface tension forces and 
capillary pressure are primarily responsible for initial granules formation. The main 
advantage is it meets the requirements of tablet formulation and main disadvantage is 
it requires many steps in process, which is time consuming. 
 
1.9   Dry granulation1,2  
 The dry granulation process is used to form granules without using a liquid 
solution, this type of process is recommended for products, which are sensitive to 
moisture and heat. Forming granules without moisture requires compacting and 
densifing the powder. Dry granulation can be done on a tablet press slugging tooling. 
On large-scale roller compactor commonly referred to as a chilsonator. The 
compacted mass is called slugs and the process is known as slugging. The slugs are 
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screened or milled to produce a granular form of tablet materials, which have the 
good properties then original powder mixture. 
 The main advantage of granulation is it requires less equipment and eliminates 
the addition of moisture and the application of heat, as found in wet massing and dry 
steps of the wet granulation method. 
 
1.10 Other technologies 
The other technologies used for manufacturing of water dispersible 
tablets are as follows 
• Freeze drying 
• Moulding 
• Sublimation 
• Spray drying 
• Mass extrusion 
1.11 Patented technologies 
• Zydus technology 
• Oroslov technology 
• Durasolv technology 
• Wow technology 
• Flash tab technology 
• Flash dose technology 
• Oraquick technology 
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In present work, an attempt was made to explore the use of Natural gums for 
both masking taste and as super disintegrating agents.  
The advantages of such tablets will be that the patient can swallow the tablets 
in the form of a liquid as they disintegrate quickly when in contact with saliva4. The 
bitter taste of the drug cannot be felt with correct selection of ion exchange resin, drug 
resonates comes into contact with the acidic environment of the stomach, the complex 
is broken down quickly and completely15. The drug is released form the resinate 
directly into solution and then absorbed in the usual way. 
Such tablets may also be used dispersible tablet, which will be of value in 
pediatric patients and those who are not co-operative. 
Various techniques used for preparing mouth dissolving tablets15 are by freeze 
drying, moulding, sublimation, spray drying, mass-extrusion and by direct 
compression. Patented technologies for mouth dissolving tablets are zydis technology 
durasolv technology, ora solv technology, flash dose technology, wow technology and 
flash tab technology. 
Freeze drying :  
A process in which water is sublimated from the product after freezing, is 
called freeze drying. Freeze-dried forms offer more rapid dissolution than other 
available solid products. The lyophilization process imparts glossy amorphous 
structure to the bulking agent and some times to the drug, thereby enhancing the 
dissolution characteristics of the formulation. 
Moulding: 
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Tablets produced by moulding are solid dispersions. Physical form of the drug 
in the tablets depend whether and to what extent, it dissolves in the molten carrier. 
The drug can exist as discrete particles or micro particles dispersed in the matrix. It 
can dissolve totally in the molten carrier to form solid solution or dissolve partially in 
the molten carrier and the remaining particles stay undissolved and dispersed in the 
matrix. Disintegration time, drug dissolution rate and mouth feel will depend on the 
type of dispersion or dissolution. 
Sublimation: 
Compressed tablets composed of highly water soluble excipients as tablet 
material often do not dissolve rapidly in the water. Porous tablets that exhibit good 
mechanical strength and dissolve quickly. Inert solid ingredients {ex: urea, 
ammonium carbonate, camphor, naphthalene) were added to other tablet excipients 
and the blend was compressed into tablet. Removal of volatile material by 
sublimation generated a porous structure. 
Spray-Drying: 
 Highly porous and fine powders can be produced by spray drying, as the 
processing solvent is evaporated rapidly during spray drying. For fast dissolving 
tablets, they developed formulation by using mannitol as bulking agent, hydrolysed 
and non-hydrolysed gelation as support matrix, sodium, starch glycolate as 
disintegrant and acidic material (ex.citric acid) and/or alkali material (ex.NaHCO3) to 
enhance disintegration and dissolution. When immersed in an aqueous medium, the 
tablets compressed from spray-dried powder, disintegrated within 20 seconds). 
Mass-Extrusion: 
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This technology involves softening the active blend using the solvent mixture 
of water soluble polyethylene glycol using methanol and expulsion of softened  mass 
through the extruder or syringe to get a cylinder of the product into even segments 
using heated blade to form tablets. The dried cylinder can also be used to coat 
granules of bitter tasting drugs and thereby masking their bitter taste. 
Direct Compression: 
It is the easiest way to manufacture tablets. Conventional equipment, 
commonly available excipients and a limited number of processing steps are involved 
in direct compression. Directly compressed tablets disintegration and solubilization 
depends on single or combined action of disintegrants, water soluble excipients and 
effervescent agent. Disintegrant efficacy is strongly affected by tablet size and 
hardness. Large and hard tablets have disintegration time more than that usually 
required. As consequences, products with optimal disintegration properties often have 
medium to small size and / or high friability and low hardness. Breakage of tablet 
edges during handling and tablet rupture during the opening of blister alveolus, all 
result from insufficient physical resistance. 
 Disintegrants have major role in the disintegration and dissolution process of 
mouth dissolving Tablets made by direct compression. To ensure a high disintegration 
rate, choice  of suitable type and an optimal amount of disintegrant is important. Other 
formulation components such as water soluble excipients or effervescent agents can 
further enhance dissolution or disintegration properties. But main drawback of using 
effervescent excipients is their highly hygroscopic nature. 
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 The understanding of disintegrant properties and their effect on formulation 
has advanced during last few years, particularly regarding so called super 
disintegrants. 
Disintegration efficiency is based on force equivalent concept, which is the 
combined measurement of swelling force development and amount of water 
absorption. Force equivalent expresses the capability of disintegrant to transform 
absorbed water into swelling force. The optimization of tablet disintegration was 
defined by means of disintegrant critical concentration. Below this concentration, the 
tablet disintegration time is inversely proportional to disintegrant concentration and 
above that disintegration time remains approximately constant or even increases. 
Zydis Technology: 
Zydis formulation is a unique freeze dried tablet in which drug is physically 
entrapped or dissolved within the matrix of fast-dissolving carrier material. When 
zydis units are put into the mouth, the freeze-dried structure disintegrates 
instantaneously and does not require water to aid swallowing. The zydis matrix is 
composed of many materials designed to achieve a number of objectives. To impart 
strength and resilience during handling, polymers such as gelatin, dextran or alginates 
are incorporated. These form a glossy amorphous structure, which imparts strength. 
Durasolv Technology: 
Durasolv is the patented technology of CIMA labs. The tablets made by this 
technology consists of a drug, fillers and a lubricant. Tablets are prepared by using 
conventional tableting equipment and have good rigidity. These can be packaged into 
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conventional packaging system like blisters. Durasolv is an appropriate technology 
for products requiring low amounts of active ingredients. 
Orasolv Technology: 
Orasolv technology has been developed by CIMA labs. In this system active 
medicament is taste masked. It also contains effervescent disintegrating agent. Tablets 
are made by direct compression technique at low compression force in order to 
minimize oral minimize oral dissolution time. Conventional blenders and tablet 
machine is used to produce the tablets. The tablets produced are soft and friable and 
packaged in specially designed pick and place system. 
Flash Dose Technology: 
Flash dose technology has been patented by Fuisz. Nurofen meltlet, a new 
form of Ibuprofen as melt-in-mouth tablets. Flash dose tablets consists of self binding 
shearform matrix termed as “floss”. Shearform matrices are prepared by flash heat 
processing. 
Wowtab Technology: 
Wowtab technology is patented by Yarnanouchi Pharmaceutical Co. Wow 
means “Without water”. In this process, combination of low mouldability saccharides 
and high mouldability saccharides is used to obtain a rapidly melting strong tablet. 
The active ingredient is mixed with a low mouldability saccharide and granulated 
with a high mouldability saccharide and compressed into tablet. 
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Flashtab Technology: 
Prographarm laboratories has patented the Flashtab technology. Tablets 
prepared by this system consists of an active ingredient in the form of microcrystals. 
Drug microgranulesmay be prepared by using the conventional techniques like 
coacervation, micro encapsulation, and extrusion. All the processing utilized 
conventional tableting technology. 
1.12 Tablet Trouble Shooting1  
Table No 01: Tablet Trouble Shooting1 
PROBLEMS CAUSES REMEDY 
Capping & Lamination 
Granulation too dry, Increase moisture 
content, 
Compression too hard, Reduce compression pressure, 
Damaged upper punches, Replace the tools 
which damaged, 
Less binders in granules, Increase binders, 
Air present in granules 
which can not escape 
while compression, 
Use tapered dies, 
Chipping 
Damaged punches or dies, 
Replace the damage 
punches or dies, 
Reduce the 
compression speed, 
Compression too fast, 
Increase the 
compression 
pressure, 
Compression too soft,   
Delayed Disintegration 
Compression too hard, 
Reduce the 
compression 
pressure, 
Improve the 
granulation, 
Over granulation, 
Reduce the blending 
time of lubrication, Excess blending time of lubricants or glidant, 
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Soft tablet 
Granulation too dry, Increase the 
moisture, 
Machine too fast, Reduce machine 
speed, 
Excess lubrication, Decrease the lubrication, 
Compression too soft, 
Increase the 
compression 
pressure, 
Hard Tablets 
Compression too hard, Reduce compression pressure, 
Uneven granulation, Improve granulation, 
Sticking & Picking 
Compression too soft, 
Increase 
compression 
pressure, 
Uneven granulation, Improve granulation, 
More fines in blend, 
Reduce moister 
content in 
granulation, 
Moister content in 
granules, Use dehumidifier, 
High relative humidity, Improve lubrication, 
Improper  lubrication, Polish the punches, 
Damage of upper punch, Buffing the punches 
with lubricants, 
Non Uniform Weight 
Non uniform granules, Provide uniform granules, 
Restricted free flow 
granules, 
Add Glidant to 
improve the flow of 
granules, 
Granules sticking too 
lower punches, Improve lubrication, 
Feed frame / hopper flow 
restricted, 
Adjust the hopper to 
get free flow, 
Black Mark On Tablets 
Improper feed frame 
setting, 
Improve feed frame 
setting, 
Excessive moisture, Avoid excess 
moisture, 
Over sized granules, Reduce granule size, 
Granules having black 
particles prior to 
compression, 
Reduce granules size 
Lubrication or oil may be 
contaminating the powder, 
Avoid 
contamination with 
Greece or oil, 
Collar formation Too much fines, Reduce fines, 
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Dissolution 
Large granules, Reduce granules 
size, 
Tablet too hard, Reduce tablet hardness, 
Excess lubrication, Reduce compression hardness. 
 
 
Choice of Mucolytic agents5,6 
• Choice of mucolytic agent depends on 
• Availability 
• Efficacy 
• Safety 
• Cost 
Guaphenesin, diphenhydramine are probably the most widely used Mucolytic 
agents  
 
1.14 Dispersible tablet1,6 
 Definition:- Dispersible tablet are uncoated tablet that produce a uniform and 
immediate dispersion in water. They should disintegrate with in three minutes and 
produce a uniform dispersion and passes through seive no:22 when dispersed in 
water. Dispersible tablet are formulated for pediatric and geriatric use or for patients 
who has difficulty in swallowing tablets. 
                       The chief advantage is quicker absorption and onset effect. They are 
generally prepared for geriatric or pediatric patients or those who are having 
difficulty in swallowing tablets. They dissolve in mouth with in few seconds to 
minutes 
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 1.14.1 Ideal characteristics of dispersible tablets5:- 
• Should easily disintegrate and dissolves in water 
• Masks and overcome unacceptable taste of drug. 
• They should have high drug loading capacity. 
• They should have pleasant feel in mouth during administration. 
• They should have negligible or no residue in oral cavity after administration 
of dosage form. 
• They should have low sensitivity against environment conditions like 
moisture, temperature, humidity and other environmental conditions. 
•  Easy administration for mentally ill, disabled and uncooperative patients. 
1.14.2 Advantages of dispersible tablets1,7:- 
• Little water is required to swallow the dosage form which is highly   
convenient feature for patients who are travelling and do not have access to 
water. 
• Free of risk of suffocation due to physical obstruction when swallowed, thus 
offering improved safety. 
• Rapid disintegration and absorption of drug, which will produce quick onset 
of action after administration. 
• Quick absorption from the GIT improves bioavailability and reduces 
unwanted effect caused by the drug .E.g. gastro intestinal irritation caused 
by NSAIDS and also improve patient compliance. 
• Drug and dosage form stability should achieve. 
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1.14.3 Disadvantages of dispersible tablets1,7:- 
• Most fast disintegrating tablet lack the mechanical strength common to 
traditional tablet. Many products are very lightweight and fragile requiring 
them to be individually packaged in separate conditions. Patients should be 
advised not to push these tablets through the foil film, but instead, peel the 
film back to release the fast-dissolving tablet. 
• Due to the formulation of fast disintegrating tablets which also more 
susceptible to degradation via temperature and humidity. Some of the newest 
fast disintegrating tablet formulation is dispensed in a conventional stock 
bottle. Pharmacists are advised to take care when dispensing such 
formulation to ensure they are not exposed to high level of moisture or 
humidity. Excess handling of tablets can introduce enough moisture to 
initiate dissolution of the tablet matrix. 
1.14.4 Mechanism of super disintegrants 
• Because of heat of wetting 
• Swelling 
• Porosity and capillary action 
• Due to disintegrating particle/particle repulsive forces 
• Due to deformation 
• Due to release of gases 
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1.15 Drugs to be promising in corporated in dispersible tablets 
Analgesics and anti inflammatory agents - 
Paracetamol, diclofenac, lornoxicam, piroxicam, aceclofenac, ibuprofen, 
naproxen, ketoprofen,phenylbutazone, nimesulide. 
Anthelmintic – 
Piperazine, albenbazole, metronidazole, thiabendazole, niclosamide. 
Anti coagulants – 
Heparin, warfarin, phenindione, ancrod,danaparoid, 
acenocoumarol,ethyldascoumacetate, lepirudin 
Antiepileptics – 
Lomotrigine, phenobarbitone, phenytoin, primidone, carbamazepine, 
valproic acid, diazepam, gabapentin, zonisamide, tiagabine, clobazam 
Anti gout drugs – 
Probenecid, allopurinol, sulfinpyrazone 
Anti hypertensive drugs – 
Furosemide, enalapril, captopril, losartan, telmisatran, verapamil, 
propranolol, atenolol, carvedilol, terazosin, clonidine, methyl dopa, 
hydralazine, sodium nitro prusside, ramipril, candesartan, diltiazem, 
nifedipine, amlodipine, metoprolol 
Anti malarials – 
Cloroquine, amodiaquine, mefloquina, quinine, quinidina, 
pyrimethamine, sulfadoxine 
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Antifungal – 
Clotrimazole, miconazole, econazole, ketoconazole, voriconazyle, 
itraconazole, fluconazole, oxiconazole, benzoic acid, undecylenic acid, 
tolnaftate, butenafine, sodium thiosulfate 
Anti thyroid – 
Propylthiouracil, methimazole carbimazole, perchlorates, thiocyanates, 
iodine, organic iodide 
Sedatives and hypnotics – 
Phenobarbitone, butobarbitone, thiopentone, diazepam, flurazepam, 
nitrazepam, lorazepam, clobazam, clonazepam, zopiclone, zolpidem, 
zaleplon, oxazepam, alprazolam 
Cardiac inotropic agents – 
Digoxin, dobutamine, dopamine, amrinone, furosemide, hydralazine, 
bisoprolol, metaprolol, spironolactone, carvedilol, nitroprussude, 
milrinone 
Diuretics – 
Furosemide, torasemide, hydrochlorothiazide, clopamide, benzthiazide, 
hydroflumethiazide, metolazone, atetazolamide, mannitol, isosorbide, 
glycerol, spironolactone, amiloride, triamterene, xipamide, indapamide, 
bumetanide 
Anti parkinsonian – 
Levodopa, cabidopa, benserazide, ropinirole, pramipexole, selegiline, 
tolcapone, entacapone, amantadine, biperiden, procyclidine, 
orphenadrine, promethazine 
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Gastro intestinal agents – 
Ranitidine, cimitidine, roxatidine, famotidine, omeprazole, rabeprazole, 
pantoprazole, lonsoprazole, oxyphenonium, misoprostol, sodium 
bicarbonate, magnesium hydroxide 
Anti histamines - 
Levocetirizine, cetirizine, fexofenadine, clemastine, cyclizine, 
mebhydroline, chlorpheniramine, meclizine, buclizine, hydroxyzine, 
promethazine, diphenhydramine, dimenhydrinate, montelukast 
Hypolipidaemic drugs – 
Lovastatin, simvastatin, pravastatin, atorvastatin, rosuvastatin, 
clofibrate, fenofibrate, bezafibrate, gemfibrozil, nicotinic acid, 
ezetimibe, gugulipid 
Nitrates and other angina drugs – 
Glyceryl trinitrate, isosorbide dinitrate, erythrityl tetranitrate, 
propronolol, atenolol, metoprolol, varapamil, nifedipine, nimodipine, 
felodipine, amlodipine, benidipine, lacidipine, nicorandil, dipyridamole, 
ranolazine, trimetazidine, oxyphedrine 
Opioid analgesics – 
Morphine, codeine, thebaine, papaverine, noscapine Other drugs such as 
proteins, peptides, recombinant drugs, sex hormones stimulants, neuro 
muscular agents were also used in the preparation of the dispersible 
agents 
Local anesthetics – 
Procaine, chloroprocaine, prilocaine, lidocaine, tetracaine, bupivacaine, 
ropivacaine, dibucaine, cocaine, benoxinate, oxethazaine, benzocaine 
Chapter – 1                                                                                                        INTRODUCTION 
 
Department of pharmaceutics                      30            JKKMMRF college of pharmacy  
 
1.16 Commercially available various dispersible tablets 
Table no -2  Commercially available various dispersible tablets 
Trade name Active ingredient 
Feldene fast melt Piroxicam 
Claritin redi Tab Loratidine 
Maxalt MLT Rizatriptan 
Zyprexia Olanzepine 
Pepcid RPD Fomotidine 
Zofran ZMT Ondensetron 
Zooming ZMT Zolmitriptan 
Zelaper TM Selegilline 
Tempra quicklets Acetaminophen 
Febrectol Paracetamol 
Nimulid MDT Nimesulide 
Torrox MT Rotecoxib 
Olanex instab Olazapine 
Romilast Montelukast 
Banedryl fast melt Diphenhydramine 
pseudoephedrine 
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1.17 DISEASE PROFILE  
1.17.1 Chronic Obstructive Airway Disease 
 
Chronic obstructive airway disease is a chronic diffuse irreversible 
inflammatory airflow obstruction of lungs. This leads to a limitation of the flow of air 
to and from the lungs causing shortness of breath (FSK Barar 2000). 
 COAD includes two main diseases: 
• Chronic bronchitis 
• Emphysema 
 Alternative term include COPD & COLD. 
 
Fig No 2: Healthy alveoli and COPD affected Alveoli. 
 
 
 
 
1.17.1.1 Epidemology 
• In UK 30000 death per year due to COPD, 12% hospitalized. 
• Incidence of COPD in smokers is 15%. 
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• In US 10.2 millions have COPD. 
• Incidence of COPD in non smokers in is 5%. 
1.17.1.2 Ethiology 
• Smoking    : - Increased smoking increases the chance of COPD. 
• AGE          : - Increase in age results in ventilatory impairment. 
• Gender       : - Both male and female has the possibility. 
• Occupation: - Workers in coal, gold mining, cement etc  has the possibility. 
• Genetic factors: - deficiency in α1 antitrypsin, tissue necrosis etc. 
• Air pollution: - increase in urban areas than rural areas. 
 
1.17.1.3. Classification 
    Two main types: 
• Chronic Bronchitis. 
• Emphysema. 
 
1.17.2. Chronic Bronchitis 
       
Chornic bronchitis is a condition of excessive mucus production by 
tracheobronchial tree which results in air way obstruction due to edema and bronchial 
inflammation. 
        Bronchits is considered chronic because cough produce more than 30ml of 
sputum in 24hrs for atleast 3 months of the year for the two consecutive years.  
 
 
 
Chapter – 1                                 
Department of pharmaceutics
 
Fig No 3: 
    
        
 
1.17.2.1. SIGNS AND SYMPTOMS
• Cough. 
• Sputum production.
• Frequent infections.
• Intermittent dyspnea.
• Oedema. 
• Plethora ( excess of blood).
• Cyanosis. 
• Wheezing. 
• Diminished breath sound.
 
1.17.2.2 Diagnosis 
 Sputum Inspetion
• Thick mucopurulent sputum.
• Microscopic analysis detect neutrophills and micro organisms.
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 Blood Analysis 
• Polycythemia due to erythropoiesis. 
• Increased WBC count due to bacterial infection. 
 Pulmonary Function Test 
• Normal in early disease stage. 
• Later increase in RV, decrease in FEV. 
 Chest Cardiograph 
• Lung hyperinflation. 
• Increased broncho vascular marking. 
 ECG 
• Right ventricular hypertrophy.  
 
1.17.2.3. Pathophysiology 
 
        There are two pathological process underlying development of chronic 
bronchitis. 
A) Hypersecretory disorder characterized by expectoration with increasing 
susceptibility to respiratory infections. Hypersecretion of thick and viscous  
mucus leads to distension of alveoli and loss of gas exchange function. 
Accumulation of pus and infected mucus lead to chronic viral and bacterial 
infections. 
B) Alveolar distension and destruction results in distortion of blood vesels closely 
associated with alveoli lead to increase in BP in pulmonary circulation. 
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1.17.3. Emphysema 
 
       It is defined as a permanent change in the anatomy of lungs with enlargement and 
destruction of the alveoli and respiratory bronchioles that result in deterioration in gas  
exchange and impared ventilation (Paul L. Munson 2001).  
Fig No 4: Healthy alveoli and Emphysema affected alveoli. 
 
 
 
1.17.3.1. Signs and Symptoms 
• Minimal cough. 
• Scant sputum. 
• Dyspnea. 
• Weight loss. 
• Occational infections. 
• Barrel chest. 
• Diminished breath sound. 
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1.17.3.2. DIAGNOSIS 
 Sputum Inspection 
• Scanty sputum. 
• Infections are less frequent than in chronic bronchitis. 
 Blood Analysis 
• Decreased AAT level. 
 Pulmonary function Test 
• Normal or increased static lung compliance, decreased FEV, increased TLC 
and RV. 
 Chest cardiograph 
• Lung hyperinflation. 
• Flattened diaphragm 
• Vertical heart. 
• Decreased vascular marking in lungs. 
 
1.17.3.3. Pathophysiology 
• Loss of available gas exchange surface leads to increase in dead space and 
impared gas exchange. 
• Loss of elastic recoil in small airways leads to a tendancy to collapse 
particularly during expiration and increase thoracic gas volume and 
hyperinflation of lungs. 
Two types 
• Centrilobular emphysema: - destruction of respiratory bronchioles, 
alveolar ducts and alveoli. 
• Panacinar emphysema: - due to α1 – antitrypsin deficiency. 
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1.17.4 Pharmacological Treatment (K.D. Tripathi 2008) 
 
A) Prophylactic Treatment 
• Single dose of pneumococcal vaccine. 
• Annual influenza vaccination. 
 
B) Broncho dialators 
• β2 agonist 
• Short acting: Albuterol, Levabuterol. 
• Long acting: Salmetrol, Furmeterol. 
• Anti cholinergics 
• Short acting: Ipratropium bromide. 
• Long acting: Tiotropium bromide. 
• Methyl Xanthines: Theophylline. 
C) Mucolytics 
• Bromhexine, Ambroxol HCl, Iodinated glycerol. 
 
D) Cortciosteriods 
• Systemic   :   Hydrocortisone, Prednisolone. 
• Inhalation:   Beclomethasone dipropionate, Budesonide. 
 
 
E) Expectorants 
• Guaiphenesin. 
  
F) Antibiotics 
• 2nd Genaration cephalosporin: Cefuroxime, Cefactor. 
• β Lactum: Amoxicillin. 
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• Macrolides: Azithromycin. 
• Oral fluoroquinolone: Ciprofloxacin, Gatifloxacin. 
 
G) Antioxidants  
• N- acetyl cysteine 
 
1.17.5 Broncho Pulmonary Disease 
                 
 Ambroxol is indicated as “secretolytic therapy in broncho pulmonary diseases 
associated with abnormal mucus secretion and impaired mucus transport. It promotes 
mucus clearance, facilitates expectoration and eases productive cough, allowing 
patients to breathe freely and deeply. A sustained release dosage form with 75 mg to 
be given once a day. Ambroxol is also available as dry powder sachets, inhalation 
solution, drops and ampoules as well as effervescent tablets (Michael Curtis Michael 
Walker etal 2006). 
 
1.17.6 Sore Throat 
Ambroxol also provides pain relief in acute sore throat. Pain in sore throat is 
the hallmark of acute pharyngitis. Sore throat is usually caused by a viral infection. 
The infection is self limited and the patient recovers normally after a few days. The 
patient experiences continuous pain in the throat when swallowing. The main goal of 
treatment is to reduce pain. The main property of Ambroxol for treating sore throat is 
the local anaesthetic effect (Alexander Schutz, Hans-Jürgen Gund etal 1993). 
  
1.17.7 Pulmonary Alveolar Proteinosis 
 
 Pulmonary alveolar proteinosis (PAP) is characterized by the presence of 
copious eosinophilic, periodic acid Schiff (PAS)-positive material in the alveoli and 
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by an excess of surfactant components (both lipids and proteins) in lung lavage. It 
may be present during the neonatal period or later in life. PAP is the consequence of a 
genetic defect involving the lungs, such as a mutation of the surfactant protein B (SP-
B) gene, or it can represent an aspect of a different genetic disease, such as lysinuric 
protein intolerance. The main pharmacodynamic effects of ambroxol hydrochloride 
are surfactant stimulation, mucokinetic activity and some secretagogue activity (Karl, 
1987). The lung surfactant system is a mixture of phospholipids and protein 
synthesized and secreted in the alveolar spaces primarily by type II pneumocytes. So 
type II pneumocyte stimulation with ambroxol hydrochloride can lead to chemico-
physical and functional changes in alveolar macrophages, probably through an 
increase in surfactant secretion and uptake (Luisetti et al., 1987). Thus an oral 
ambroxol hydrochloride and therapeutic BAL should be the first choice in treating 
PAP (Hisashi Suyama, Naoto Burioka etal 1999). 
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2. REVIEW OF LITERATURE 
1. Milind p wage, et al (2010) Prepared fast dissolving tablet of aceclofenac by 
direct compression method after incorporating superdisintegrants 
croscarmellose sodium, crospovidone and sodium starch glycolate. Nine 
formulation having superdisintegrant at different concentration (10, 15, 20 mg) 
level were prepared. Effect of superdisintegrant on wetting time, dispersion 
time, drug content and in vitro release has been studied.The result of the study 
shows that  tablet containing cross carmellose sodium showed excellent in 
vitro dispersion time and drug release as compared to other formulation.  
 
2. Anupama kalia, et al (2009) Formulated mouth-dissolving tablets of 
oxcarbazepine by using two different technologies, direct compression method 
and solid dispersion technology. Tablets produced by direct compression 
method contain crospovidone as a superdisintegrant and aspartame as a 
sweetener. Solid dispersions of oxcarbazepine with polyvinylpyrrolidone K-30 
and polyethylene glycol 6000 in different weight ratios were prepared with a 
view to increase its water solubility.The result of the study shows that 
Oxcarbazepine solid dispersions with polyvinylpyrrolidone K-30 in 1:2 ratios 
of drug: carrier showed maximum drug release and hence, compressed along 
with other excipients into mouth dissolving tablet. 
 
3. Sandeep B. Pathi, et al (2009)  Formulated Olanzapine quick dispersing 
tablets by direct compression method. Effect of super disintegrant 
crospovidone on wetting time, disintegration time, and drug content and in 
vitro release has been studied. A 32 factorial design was employed in 
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formulating a quick dispersible tablet. The selected independent variables 
crospovidone and hydroxypropylcellulose showed significant effect on 
dependent variables i.e. disintegration time and percent drug dissolved.The 
result of the study shows that disintegration time and percent drug dissolved 
decreased with increase in the level of crospovidone. The similarity factor f2 
was found to be 72.68 for the developed formulation indicating the release was 
similar to that of the marketed formulation. 
 
4. Snehalatha,etal(2009)Formulated  Lornoxicam  dispersible tablets using 
natural disintegrants which would release the drug rapidly with predetermined 
rate. Six batches of  Lornoxicam dispersible tablets were prepared by using 
various natural disintegrating agents in order to get required theoretical release 
profiles. The influence of the disintegrant concentration and granulation 
technique on the release of Lornoxicam was studied. The study reveals that the 
formulation prepared by direct compression exhibits better dissolution, 
disintegration at low concentration of natural disintegrants. 
 
5. Raghavendra Raon.G,et al (2009)  Formulated chlorthalidone fast dissolving 
tablet by direct compression using cogrinding and solid dispersion methods by 
using chlorthalidone as a model drug. Chlorthalidone is a well known diuretic 
used in the treatment of hypertension and edema. The half life of 
chlorthalidone is 40 hours. The major problem with this drug is erratic 
absorption from GIT, limited aqueous solubility and a high melting point, 
which may hinder dissolution causing decreased bioavailability of the drug. 
Therefore the solid dispersions and cogrinding method were followed with a 
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view to increase solubility and bioavailability.The result of the tablet 
formulation containing polyvinyl pyrrolidone K-12 solid dispersion showed 
maximum drug release than the chlorthalidone polyvinyl pyrrolidone K-12 co-
grinding method. The dissolution profile of best solid dispersion formulation 
was compared with co-grinding method formulation.  
 
6. Biraju Patel, et al (2009) developed  fast dissolving tablets of glipizide were 
prepared by direct compression method with a view to enhance patient 
compliance. Two superdisintegrants viz, crospovidone and croscarmellose 
sodium (4%, 5%, 6%) with different binders viz, pvp k-30 and pregelatinized 
starch (3%) were used. The prepared batches of tablets were evaluated for 
hardness, friability, and weight variation, disintegration, wetting time, drug 
content and in vitro dissolution studies. Based on evaluating parameters, 
Formulation prepared by using 5% croscarmellose sodium with 3% PVP K30 
was selected as optimized formulation. Finally, the optimized formulation was 
compared with marketed conventional formulation.  
 
7. Jashanjit Sing, et al (2009)formulated and optimized an orodispersible 
formulation of meloxicam using a 22 factorial design for enhanced 
bioavailability.  The tablets were made by non-aqueous wet granulation using 
crospovidone and mannitol. A 22 factorial design was used to investigate the 
amount of crospovidone and taste masking, soothening hydrophilic agent 
(mannitol), as independent variables, and disintegration time as dependent 
response. Formulated orodispersible tablets were evaluated for weight 
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variation, friability, disintegration time, drug content, wetting time, water 
absorption ratio and in vitro drug release. 
 
8. P.S. Zade, et al (2009)  formulated, evaluated & optimized fast dissolving 
tablet of Tizanidine Hydrochloride using Eudragit E 100 as a taste masking 
agent. Mass extrusion was the technique used for preparing taste masked 
granules. The tablet was prepared with three super disintegrants e.g. sodium 
starch glycolate, crosscarmellose sodium and crospovidone. The blend was 
examined for angle of repose, bulk density, tapped density and hausner’s ratio.  
The tablets were evaluated for hardness, drug content and friability and 
disintegration time.The result concluded that these tablet disintegration in oral 
cavity was also tested and was found to be 22 sec. Other tablets were prepared 
by using camphor as sublimating agent. It was concluded that tablets prepared 
by addition of superdisintegrant has less disintegration time than those 
prepared by sublimation method. 
 
9. NG Raghavendra Rao, et al (2009) studied the developed the fast dissolving 
tablets of poorly soluble carbamazepine by the direct compression technique 
with β -cyclodextrin complexes using various super disintegrants like Indion-
414, croscarmellose sodium, crospovidone and sodium starch glycolate. The 
result of the formulation shows excellent rate of absorption and/or the extent 
of bioavailability for such a poor soluble drug is controlled by rate of 
dissolution in gastrointestinal fluids. Hence, to enhance the solubility of the 
drug, a complex of carbamazepine was prepared with β -cyclodextrin and this 
complex was compressed into tablets.  
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10. Parmar R.B., et al (2009) formulated and evaluated the Domperidone, an 
antiemetic drug, has been used as an add-on treatment in adults and children. 
As precision of dosing and patient’s compliance become important 
prerequisite for quick relief from emesis, there is a need to develop a 
formulation for this drug which overcomes problems such as difficulty in 
swallowing, inconvenience in administration while traveling and better 
compliance. Hence, the present research work was held to develop a fast 
dissolving tablet of domperidone, prepared with Avicel PH 102 and Sodium 
Starch Glycolate by direct compression method.The result of the studies shows 
an effective, pleasant tasting formulation was found to have a good hardness 
of 3 kg/cm2, disintegration time of 27+1 seconds and in vitro drug release of 
not less than 95% within 30 minutes. The drug release was found to be 
comparable with the marketed dispersible tablet. 
 
11. S Furtado, et al (2008)studied the development and characterization 
Orodispersible tablets of famotidine were prepared using camphor as 
subliming agent and sodium starch glycollate together with crosscarmellose 
sodium as superdisintegrants. The formulations were evaluated for weight 
variation, hardness, friability, drug content, wetting time, in vitro and in-vivo 
dispersion, mouth feel and in vitro dissolution.The result of the formulations 
showed low weight variation with dispersion time less than 30 seconds and 
rapid in vitro dissolution. The results revealed that the tablets containing 
subliming agent had a good dissolution profile. The drug content of all the 
formulations was within the acceptable limits of the United States 
Pharmacopoeia XXVII.  
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12. C Mallikarjuna Setty, et al (2008)developed the aceclofenac fast-dispersible 
tablets have been prepared by direct compression method. Effect of 
superdisintegrants (such as, croscarmellose sodium, sodium starch glycolate 
and crospovidone) on wetting time, disintegration time, drug content, in vitro 
release and stability parameters has been studied. The result revealed that the 
disintegration time and dissolution parameters (t
 50% and t 80% ) decreased with 
increase in the level of croscarmellose sodium. Whereas, disintegration time 
and dissolution parameters increased with increase in the level of sodium 
starch glycol ate in tablets. However, the disintegration time values did not 
reflect in the dissolution parameter values of crospovidone tablets and release 
was dependent on the aggregate size in the dissolution medium.  
 
13. Shishu, et al (2008) prepared chlorpheniramine maleate rapid disintegrating 
tablet in saliva. Bitter masked granules were prepared using aminoalkyl 
methaarcylate copolymer (Eudragit E-100) by extrusion method. 
     The result revealed that In vitro release at pH 6.8 indicate that perceivable 
amount of drug will not be realeae in saliva while percentage release (more 
than 80% in 30 min) obtained at acidic pH 1.2 stomach. These taste masked 
granules having sufficient strength of 3.5 kg/cm were evaluated. 
 
14. Mukesh Gohel, et al (2004)  developed mouth dissolve tablets of nimesulide. 
Granules containing nimesulide, camphor, crospovidone, and lactose were 
prepared by wet granulation technique. Camphor was sublimed from the dried 
granules by exposure to vacuum. The porous granules were then compressed. 
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Alternatively, tablets were first prepared and later exposed to vacuum. The 
tablets were evaluated for percentage friability, wetting time, and 
disintegration time. The results of multiple linear regression analysis revealed 
that for obtaining a rapidly disintegrating dosage form, tablets should be 
prepared using an optimum concentration of camphor and a higher percentage 
of crospovidone.The result revealed that the sublimation of camphor from 
tablets resulted in superior tablets as compared with the tablets prepared from 
granules that were exposed to vacuum. The systematic formulation approach 
helped in understanding the effect of formulation processing variables. 
 
15. S. Khalil, et al (2000) compared Lornoxicam and tenoxicam selective 
membrane sensors. The construction and general performance characteristics 
of potentiometric plastic-membrane sensors for Lornoxicam and tenoxicam 
drug-anions are described. The electroactive materials are based on ion pair 
complexes with aliquot 336S cation. Both electrodes show near Nernstian 
response over the range 10−2–10−5 mol/l, with a detection limit of about 
2.4_10−6 mol/l for Lornoxicam and 6_10−6 mol/l for tenoxicam. The 
selectivity of the electrodes to a number of organic and non-organic anions is 
reported. The electrodes proved useful in the determination of the active 
ingredient in their respective pharmaceutical preparations. The method is 
simple, rapid and does not require prior sample pre-treatment.  
 
16.  Yunxia B, et al( 1999) developed a disintegrating tablets prepared by the wet 
compression granules under low compression force and then drying the 
resulting wet mass in a circulating-air oven (wet compression method). 
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Lactose with various particle sizes was used as the incipient, and water was 
used as a wetting agent. The effect of drying time, compression force, size of 
lactose particles, and moisture content of wet granules on tablet properties 
indicated that the formation and disintegration time of tablets were related to 
the effect of the formation of solid bridges between lactose particles. The 
result shows that by optimizing compression force, size of lactose particles, 
and moisture content of the granules, tablets meeting tensile strength greater 
than 0.5 Map and disintegration time shorter than 15 s were obtained by the 
wet compression method. 
 
17. Patil Pradeep S et al (2013) Oral disintegrating tablets are emerging trend in 
Novel drug delivery system & received increasing demand & popularity due 
to ease of administration & better patient compliance .In recent years 
superdisintegrant have been employed to develop effectual mouth dissolving 
tablet & to overcome limitation of conventional tablets .In present study 
attempt was made to compare to disintegrating efficiency of natural 
superdisintegrats .Main aim of using oscimum basilicum as natural 
superdisintegrant was to achieve  quick onset of action ,increases water uptake 
with short wetting time & decreasing disintegration time by cost effective 
direct compression method. 3 preliminary batches were prepared & these are 
evaluated for precompression parameter like angle of repose, carr`s index & 
post compression parameters like wetting time, water absorption ratio,in vitro 
disintegration. Hardness, friability of all formulations found within limit. Best 
formulation F2 batch had shown good hardness, friability, disintegration time,  
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swelling time. Present study revealed that mucilage obtained from oscimum 
basilicum was effective for their disintegrating property. 
 
18. Patni Sonal D et al (2013) prepared fast dissolving tablets of Salbutamol 
sulphate by direct compression method for better patient compliance and 
immediate action in asthma. The tablets were prepared by using synthetic 
superdisintegrants (Croscarmellose sodium and Sodium starch glycolate) and 
natural superdisintegrant (mu cilage of Plantago ovata and Plantago ovata  
husk  powder) at different concentrations as 2, 4, 6, 8 and 10 %. The  Plantago 
ovata  mucilage was extracted from the seeds of  Plantago ovata  
(Plantaginaceae).The tablets were characterized for weight variation, hardness, 
friability, disintegration time, wetting time, water absorption ratio, drug 
content and  in vitro  dissolution tests. The Drug excipients compatibility 
study was performed by DSC and IR spectroscopy and no incompatibility was 
found. The tablets were  subjected for accelerated stability study at 40°C /75% 
RH and were found to be stable. The results clearly shows Natural 
superdisintegrants requires less disintegration time as compared to synthetic 
superdisintegrants. Hence present study reveals that the  fast dissolving tablets 
prepared by using mucilage of  Plantago ovata  and  husk powder of  Plantago 
ovata  as  superdisintegrants having better appearance and rapid disintegration 
time. 
 
19. Vikas Sharma et al Oral route is the most preferred route for administration 
of various drugs because it is regarded as safest, most convenient and 
economical route. Recently researcher developed the  fast disintegrating 
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tablets with improved patient compliance and convenience. Fast disintegrating 
tablets are solid dosage forms which dissolve rapidly in saliva without 
chewing and additional water. Fast disintegrating tablets overcome the 
disadvantages of conventional dosage form especially dysphagia (difficulty in 
swallowing) in paediatric and geriatric patients.  Natural  materials have  
advantages over synthetic ones since they are chemically inert, nontoxic, less 
expensive,  biodegradable and widely available. They can also be modified in 
different ways to obtain tailor- made materials for drug delivery systems and 
thus can  compete with the available synthetic  excipients. With the increasing 
interest in polymers of natural origin, the pharmaceutical world  has 
compliance to use most of them in their formulations. 
 
 
20  Vikas Sharma et al (2012)Formulated fast dissolving tablets of Carvedilol by 
using various natural superdisintegrant like  Plantago ovata, Lepidium 
sativum, Fenugreek and Guar gum. A Direct compression method was used to 
prepare fast dissolving tablets containing Carvedilol  as a model drug using 
natural superdisintegrants. Prepared formulations were evaluated for 
Precompression parameters such as micromeritic properties like angle of 
repose, %compressibility and Hausner’s ratio. Tablets were also subjected to 
Postcompression  analysis for the parameters such as weight variation, 
hardness, and friability,  in vitro  disintegration time, wetting time, drug 
content and in vitro  dissolution study. The results concluded that amongst all 
formulations, the formulation prepared with mucilage of  Plantago ovata 
showed better disintegrating property as well as the release profile than the 
other used natural superdisintegrant. 
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21 Nitin Bansal et al (2011)developed orally disintegrating tablets of ondansetron 
HCl using natural Superdisintegrants.Method:Tablets containing the drug were 
prepared by dry granulation method using different concentrations of 
superdisintegrants such as modified gum karaya, modified natural agar, 
crosscarmellose sodium and sodium starch glycollate. The formulations were 
evaluated for weight variation, hardness, friability, drug content, wetting time, 
in vitro disintegration time and in vitro dissolution study. Results:The results 
showed that modified gum karaya and modified natural agar produce rapid 
disintegration of tablets.The optimized formulation showed acceptable 
physical characteristics. The optimized batch produced complete drug release 
within 6 minutes. The incorporation of clove oil provided additional properties 
such as symptomatic relief from nausea and vomiting, good mouth feel and 
taste masking. Kinetic analysis showed that drug release from optimized 
formulation was adequately described by first order release kinetics. 
Conclusion:Modified gum karaya and modified natural agar can be used as an 
alternative superdisintegrants to commonly available synthetic and 
semisynthetic superdisintegrants due to their low cost, biocompatibility as well 
as easily availability. 
 
22. S.Vimal Kumar et al (2010) prepared the sustained release (SR) tablets of 
Ambroxol Hydrochloride by wet granulation method. The effect of 
hydrophilic matrices on the behavior of Ambroxol Hydrochloride using 
different polymers and their  combinations. The prepared tablets were 
evaluated for physical characteristics such as Hardness, Thickness, Friability, 
Weight variation, Content uniformity and In-vitro release behavior. The drug 
Chapter – 2                                                                               LITERATURE REVIEW 
 
Department of pharmaceutics                      51                                          JKKMMRF college of pharmacy  
 
 
release from the optimized formulation was found to follow zero order 
kinetics. It was also found linear in Higuchi’s plot. Thus the phenomenon of 
drug release showed that the release of optimized formulation is controlled by 
diffusion. It is concluded that as compare to other formulations, optimized 
formulation fulfilled all criteria for SR tablet dosage form.  
 
23.O.Ramana et al (2012)  investigated to develop oral controlled release matrix 
tablets of Ambroxol hydrochloride by melt granulation technique using 
hydrophilic meltable binders such as PEG 6000 and Gelucire 50/13(Stearoyl 
polyoxyl glycerides). The FT-IR and DSC analysis indicated the stability and 
compatibility of drug with excipients.The in-vitrodissolution studies of the 
matrix tablets prepared using only meltable binders released almost 90 % of 
the drug in the first 2 hours, which lead to the incorporation of HPMC K M 
into the 4formulations as a release retardant to control the drug release for a 
prolonged period of time. The formulations F3 and F6 (both containing 30% 
meltable binder and 20% HPMC K M) controlled the drug release over a 
prolonged period of time i.e. 12 hrs and exhibited drug release patterns ideal 
with the theoretical release profiles of Ambroxol hydrochloride. The 
dissolution data obtained for various formulations were fitted into zero-order, 
first order, Higuchi’s and Peppas kinetic models and results showed that the 
drug release followed first order kinetics, the profiles were linear with 
Higuchi’s plot and “n” value obtained from peppas were within 0.45 to 0.89 
      indicated (anomalous diffusion) the mechanism of drug release was diffusion 
coupled with erosion. The optimized formulations F3 and F6 showed no 
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change in theirin vitrodissolution profiles after storage at 25°C/60%RH and 
40°C/75%RH for a period of three months indicating their stability. 
 
24 K.V.R.N.S.Ramesh et al (2010) Extended release matrix tablets of ambroxol 
hydrochloride were developed employing combination of hydroxypropyl 
methyl cellulose and stearic acid as the matrix materials in different 
proportions. Tablets containing 75 mg of the drug were formulated and made 
by entrapping the drug in a waxy carrier and then by the conventional wet 
granulation method. Granules prepared were evaluated for loose bulk density, 
tapped density, compressibility index, Hausner ratio and angle of repose and 
by  determining the constants from a Kawakita plot. The prepared tablets were 
found to be of optimum hardness, uniform weight and acceptable friability. 
The release was found to be dependent on the relative proportion of hydroxyl 
propyl methyl cellulose and stearic acid. Kinetics of the drug release data was 
evaluated out by employing the relevant equations of first order, zero order, 
Higuchi square root and Korsmeyer – Peppas. The drug release data suggested 
thatthe release of the drug is first order and that the drug release is diffusion 
controlled. 
 
25.Abdul althaf S et al (2011)  developed a pharmaceutically equivalent, stable, 
cost effective and quality improved formulation of Ambroxol pellets to present 
it in the form of capsules (Modified release capsules). To achieve this goal 
various prototype formulation trails were taken and evaluated with respect to 
the various quality control such as dissolution, assay, acid resistance and 
moisture content. The active pharmaceutical ingredient Ambroxol was 
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subjected to preformulation study, and the results obtained with selected 
excipients showed good compatibility with Ambroxol. Ambroxol coated 
pellets were formulated by using commercially available pellets and Ambroxol 
coated pellets were filled by capsule filling machine. The stability ofthe 
capsules and pellet was determined by conducting “Accelerated stability 
testing” in 40°C ± 2°C / 75% ± 5%RH, 30ºC ± 2 ºC/ 65% ± 5% RH and 
25±2°C/60±5% RH conditions for 1 month. Finally, after the duration, the 
product was analyzed for content and dissolution study. By the stability 
studies, the formulated Ambroxol modified release capsules and pellets proved 
to be stable throughout the period of the storage. The Ambroxol modified 
release pellets were loaded in size 4 capsules. It showed good results in 
formulation of stable dosage. Modified release pellets have minimum volume 
in size, greater surface area and more surface of disintegration time for pellets 
in capsules. Small volumes of pellets enter into the systemic circulation very 
fast. Moreover no accumulation of drug in the body occurs. 
 
26.Anup Kumar Roy et al 2013) developed sustained release tablets .Ambroxol 
hydrochloride has relatively short plasma half life. The need for the 
administration of the drug for two to three  times a day can decrease patient 
compliance. Sustained release formulations that would maintain plasma level 
for 8-12 h might be sufficient for daily dosing of Ambroxol Hydrochloride. 
The overall objective of the present work was to develop an oral sustained 
release Ambroxol Hydrochloride tablet prepared by direct compression 
method using hydrophilic Eudragit RSPO and RLPO alone or in combination 
with hydrophobic ethylcellulose polymer as rate controlling factor. All the 
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batches were evaluated for thickness, weight variation, hardness, friability and 
drug content and  in  vitro  drug release for 12 h. The  in  vitro  drug release 
study revealed that when Eudragit RSPO, RLPO and Ethylcellulose were used 
alone as the only retarding polymer, a sustained drug  release pattern was not 
observed while, Combining Eudragit with ethylcellulose, the drug release 
pattern was observed in a sustained manner for 12 h. F7 formulation sustained 
the drug release for longer period of time as compared to other formulations. 
So F7 was selected as the best formulation. Kinetic modeling of  in vitro  
dissolution profiles revealed that the drug release mechanism ranges from 
diffusion controlled to anomalous type. Fitting the data to Korsmeyer equation 
indicated that diffusion along with erosion could be the mechanism of drug 
release. 
 
27.Km Ariful Islam et al 2009  aimed to perform stability study of Ambroxol 
Hydrochloride sustained release pellets stored in different storage conditions. 
The drug loaded beads were prepared by Extrusion-Spheronization technology 
then coated with ammonio methacrylate copolymer Type A (Eudragit RL 30 
D) and ammonio methacrylate copolymer Type B (Eudragit RS 30 D) at a 
ratio of 2:3 (8% polymer by weight on dry basis) in Fluid Bed Coater (Wurster 
column). Stability study of pellets was performed as capsule dosage form in 
Aluminium-PVDC packaging mode at room temperature, 40oC, 40o 
C/75%RH & 30oC/70%RH for three months. After one month the shape & 
size of the pellets was changed in all conditions. The color of the pellets 
remains unchanged up to the 2nd month in all conditions except at 40 o 
C/75%RH and in this case some pellets become brown. But after 3rd month, 
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pellets become brownish in all conditions except at room temperature. At RT 
the color of pellets remains unchanged during the stability study. The mean 
drug content decreased gradually in all conditions. In acid media the initial 
drug release was 23% but after 1st month it was decreased to 13-15% in all 
conditions. In the buffer media (pH 6.8) the drug release was increased a little 
bit in all conditions except at 300 C/70%RH with the passes of storage time. 
Stability studies at 30o C/70%RH revealed consistent drug release (f2>50) 
throughout the stability period. The physical properties of pellets as well as the 
in vitro release profile of the drug was found to be a function of the different  
     storage conditions as well as the physico-chemical nature of the polymers. 
 
28 Bharat V. Jain et al 2013 prepared taste  masked  suspension of  Ambroxol 
Hydrochloride by  abating  the intensely bitter taste of  Ambroxol  
Hydrochloride.  Taste abatement was done by complexing of  Ambroxol  
hydrochloride with different Ion Exchange Resins (IER) like Tulsion 335 and 
Indion 214 in different ratios. The prepared suspensions were evaluated for 
taste, drug  content, particle size, viscosity,  sedimentation volume and drug 
release. The  resonates  prepared with drug-  T335  ratio (1:2) at pH 8, gave 
maximum drug loading. Suspension containing above resinates showed more 
than 80%  In vitro  drug release within 30 min. Prepared formulation also 
showed good stability and can retain its palatable taste.The developed 
formulation was an additional advantage like simplification of manufacturing 
procedure and is economical.Thus, the “patientfriendly dosage form” of bitter 
drugs, especially for pediatric, geriatric, bedridden, and noncooperative 
patients, can be successfully formulated using this technology. 
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3.AIM AND PLAN OF WORK 
  
AIM 
              The aim of work is to formulate fast disintegrating Ambroxol hydrochloride 
tablet with sufficient mechanical integrity and to achieve faster disintegration for the 
patient convenience. 
 
The objective of present study is: 
   To develop dispersible tablet by simple and cost effective technique. 
 
Criteria for selection of work:  
• To develop and evaluate the Ambroxol Hydrochloride dispersible tablet by 
direct compression method. 
• To develop and evaluate the Ambroxol hydrochloride dispersible tablet with 
two different natural  superdisintegrants with different concentrations. 
• To study the effect of natural superdisintegrants on  dispersible tablet. 
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PLAN OF THE WORK 
The study was planned to carry out as follows 
1.Procurement of drug, polymer and other excipients 
2. Preparation of mixed blend of drug and excipients by using  natural 
superdisintegrants 
• Guar gum 
• Karaya gum 
3.Checking Drug and Excipient compatability by FTIR studies 
4.Evaluation of powder mixed blend of Drug and Excipients 
• Angle of repose 
• Bulk density 
• Tapped density 
• Compressibility index 
• Hausner ratio 
5. Compression of tablet by  Direct Compression Method 
6. Evaluation of compressed tablets 
• Weight variation 
• Hardness 
• Friability 
• Estimation of drug content 
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• Disintegration time 
• Water uptake test 
7. Invitro release studies using buffer 
• 6.8 Phosphate buffer 
8.Drug release kinetics 
9.Stability studies  
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4.MATERIALS AND METHODS 
 List of drugs & excipients used for the formulation 
The following drugs and excipients used to carry out the study  
Table No 3: List of drugs & excipients 
S.No. Name of the material Name of supplier 
1 Ambroxol HCl Yarrow chemicals, Mumbai 
2 Guar gum         SD Fine chemicals 
3 Karaya gum SD Fine chemicals 
4 Microcrystalline cellulose Yarrow chemicals, Mumbai 
5 Aspertame Hetero chemicals,Hyderabad 
6 Magnesium stearate Thomas Baker Pvt ltd,Mumbai 
7 Mannitol Thomas Baker Pvt ltd,Mumbai 
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 List of Equipments 
The following equipments were used for the studies  
Table No: 4 List of Equipments 
Instrument Used Model No. Make 
FTIR Spectrophotometer 8400S Shimadzu, Japan 
UV–Visible Spectrophotometer UV – 3000+ LAB INDIA 
Tablet Compression Machine Mini Press Rimek 
Tablet Dissolution Tester USP 
(XXIII) 
DS-8000 LAB INDIA 
Tablet disintegration apparatos N.S Lab India 
Environmental test chamber JRIC – 11A Oswald 
Electronic Balance AGN-303EC AXIS 
Tablet hardness tester N.S Monsanto 
Roche's friabilator N.S Scientific 
Hot air oven PYROCON York Scientific Ind., Mumbai 
Digital pH meter PHAN LAB INDIA 
Melting Point apparatus N.S Biotech India Ltd. 
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4.DRUG PROFILE 
DRUG PROFILE 
4.1 Ambroxol hydrochloride 
Structure:  
 
Molecular formula: C13 H18 Br2 N2O Hcl 
Chemical name: Trans 4,2-amino-3, 5 dibromo benzy1 amino) cyclohexanol hydrochloride. 
Appearance: A white or almost white crystalline powder, odourless or almost odourless. 
Solubility: Soluble in methanol 
N,N – dimethy1 formamide 
Slightly solube in water and ethanol 
Practically insoluble in chloroform and benzene. 
Storage : Ambroxo hydrochloride should be protected from light. 
Therapeutic category: 
Expectorant: enhanced mucolytic. 
Respiratory disorders: 
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 Used in a variety of respiratory disorders including chronic bronchitis 
 Cystic fibrosis and infant respiratory distress syndrome. Also used in the treatment of 
cough. 
Uricosuric action:  
It also shows uricosuirc effect. The minimum effective dose of lowering plasma 
uricacid concentrations was found to be between 250 mg and 500mg daily given in 2 divided 
doses. Although these doses are much higher than those used to treat broncho pulmonary 
disease, doses as high as 1 gram daily were well tolerated.  
Daily dose:  
30 to 120 mg has been given by mouth in 2 to 3 divided doses. 
Adverse effect:  
Hyper sensitivity : A report of contact allergy to Ambroxol. 
Mechanism of action: 
 Ambroxol hydrochloride is a potent mucolytic & mucokinetic, capable of  including 
bronchial secretion. It depolymerises mucopolysaccharides directly as well as by liberatin 
lysosomal enzymes network of fibres in tenacious sputum is broken. It is particularly useful in 
if mucus plugs are present. (Tripti KD, 2003) 
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Pharmacokinetics: 
 Ambroxol hydrochloride is rapidly absorbed from the gastrointestinal tract and under 
goes extensive first pass metabolism in the liver. It is widely distributed to body tissues. 
About 85% of the drug is excreted as metabolites. It is highly found to plasma proteins. It has 
a terminal half life about 12hours. 
 Ambroxol hydrochloride crosses the blood brain barrier and small amounts cross the 
placenta. Administration of Ambroxol hydrochloride by mouth to healthy subjects produced 
peak plasma concentration after about 1 hour. Only small amounts were excreted unchanged. 
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Excipients Profile15 
An ideal bulk excipient for Fast Dissolving Tablet should have the following properties 
• Disperses and dissolve in water within few seconds without leaving any residue. 
• Masks the offensive taste and offers a pleasant mouth feel. 
• Enable sufficient drug loading and reminds relatively unaffected by changes in humidity or 
temperature. 
• Preferably direct compressible and yield sufficiently robust tablet to with stand manufacturing, 
packaging and transportation, yet disperses quickly in water. 
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                                                   4.2. Guar Gum 
Nonproprietary Names :  BP: Guar Galactomannan 
      PhEur: Guar Galactomannan 
      USP-NF: Guar Gum  
Synonyms: Galactosol; guar flour; guar 
galactomannanum; jaguar gum;Meyprogat; 
Meyprodor; Meyprofin. 
Empirical Formula :  (C6H12O6) n 
Chemical name :  Galactomannan polysaccharide 
Structural Formula: 
 
Functional Category: 
Suspending agent; tablet binder; tablet disintegrant; viscosity increasing agent. 
Description: 
Guar gum occurs as an odorless or nearly odorless, white to yellowish-white granules 
with a bland taste. 
Chapter - 4                              MATERIALS AND METHODS 
 
Department of Pharmaceutics                66              JKKMMRF College of Pharmacy 
 
Typical Properties: 
Acidity/alkalinity:pH = 5.0-7.0 (1% w/v aqueous dispersion) 
Density:1.492 g/cm3.  
Solubility: 
Practically insoluble in organic solvents and in cold or hot water. 
Stability and Storage Conditions: 
Guar gum granules should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
Guar gum is compatible with most other plant hydrocolloids suchastragacanth. It is 
incompatible with acetone, ethanol (95%), tannins, strong acids, and alkalis. Borate ions, if 
present in the dispersing water, will prevent the hydration of guar gum.  
Safety: 
Guar gum is widely used in foods, and oral and topical pharmaceutical formulations. 
Excessive consumption may cause gastrointestinal disturbance such as flatulence, diarrhea or 
nausea (Raymond C Rowe et al, 2009). 
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Synonyms 
Empirical Formula 
Structural formula: 
Functional Category: 
Emulsifier, stabilizer, thickening agent.
Description: 
Unground product:
having a characteristic semi
and horny. 
Powdered product:
acetic acid.  
Typical Properties: 
Solubility:Insoluble in ethanol, in water it swells to form a granular, stiff, slightly 
opalescent gel. 
Loss on drying:Not more than 20% (105
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4.2. Karaya Gum 
: Karaya, gum karaya, Sterculia, gumsterculia, 
Kadaya, Katilo, Kullo, Kuterra. 
 : (C32H48O14)n  
 
It occurs in tears of variable size and in broken irregular pieces 
-crystalline appearance; pale yellow to pinkish brown; translucent 
It occurs as pale grey to pinkish brown; a distinctive odour of 
°C, 5 h). 
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Total ash:Not more than 8% 
Acid insoluble ash:Not more than 1% 
Applications in Pharmaceutical Formulation or Technology: 
Karaya gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics, and foods as a suspending and stabilizing agent. It is also used as a thickening and 
emulsifying agent. It is nontoxic, compatible with most other pharmaceutical ingredients, and 
has good stability and viscosity properties over a wide pH and temperature range.Karaya gum 
gels show pseudoplastic behavior, the shear thinning being directly proportional to the shear 
rate. The viscosity returns to normal immediately on release of shear stress. 
Stability and Storage Conditions: 
Karaya gum should be stored in a well closed container in a cool and dry place. 
Incompatibilities: 
Karaya gum is an anionic material and is not usually compatible with cationic 
surfactants, polymers or preservatives, as precipitation occurs. Anionic and amphoteric 
surfactants at concentrations above 15% w/v cause precipitation ofKaraya gum from a 
solution. 
Safety: 
Karaya gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics, and food products, and is generally regarded as nontoxic and nonirritant at the 
levels employed as a pharmaceutical excipient. The estimated acceptable daily intake for 
Karaya gum has been set by the WHO at up to 10 mg/kg body weight.  
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4.3.MICROCRYSTALLINE CELLULOSE53 
Nonproprietary Names:  
BP: Microcrystalline Cellulose 
JP: Microcrystalline Cellulose 
PhEur: Cellulose, Microcrystalline 
USP-NF: Microcrystalline Cellulose 
 Synonyms: 
Avicel PH; Cellets; Celex; cellulose gel; hellulosum microcristallinum; Celphere; 
Ceolus KG; crystalline cellulose; E460; Emcocel; Ethispheres; Fibrocel; MCC Sanaq; 
Pharmacel; Tabulose; Vivapur. 
Chemical Name:  
Cellulose [9004-34-6] 
 Empirical Formula and Molecular Weight: 
(C6H10O5)n ,36 000 
where n is 220. 
Structural Formula: 
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Functional Category: 
Adsorbent; suspending agent; tablet and capsule diluent; tablet disintegrant. 
Applications in Pharmaceutical Formulation or Technology: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-granulation 
and direct-compression processes. In addition to its use as a binder/diluent, microcrystalline 
cellulose also has some lubricant and disintegrantproperties that make it useful in tableting. 
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4.4. MAGNESIUM STEARATE53 
Non-Proprietary Names 
BP: Magnesium stearate; IP: Magnesium stearate 
PhEur: Magnesii stearas; USPNF: Magnesium stearate 
Synonyms: Magnesium octadecanoate, octadecanoic acid, magnesium salt, stearic acid, 
magnesium salt. 
Chemical Name and CAS Registry Number: Octadecanoic acid magnesium salt [557-04-0] 
Empirical Formula: C36H70MgO4  
Molecular Weight: 591.34 
The USPNF 23 describes magnesium stearate as a compound of magnesium with a 
mixture of solid organic acids that consists chiefly of variable proportions of magnesium 
stearate and magnesium palmitate (C32H62MgO4). The PhEur 2005 describes magnesium 
stearate as a mixture of magnesium salts of different fatty acids consisting mainly of stearic 
acid and palmitic acid and in minor proportions other fatty acids. 
Structural Formula 
[CH3 (CH2)16COO]2Mg 
Description 
 Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odour of stearic acid and a characteristic taste. The 
powder is greasy to touch and readily adheres to the skin. 
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Physical Properties : 
Crystalline Forms: High-purity magnesium stearate has been isolated as a trihydrate, a 
dehydrate and an anhydrate. 
Density (bulk): 0.159 g/cm3 
Density (tapped): 0.286 g/cm3 
Density (true): 1.092 g/cm3 
Flash point: 250°C 
Flowability: Poorly flowing, cohesive powder. 
Melting Range: 117–150°C (commercial samples); 126–130°C (high purity magnesium 
stearate). 
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water; slightly soluble in 
warm benzene and warm ethanol (95%). 
Specific Surface Area: 1.6–14.8 m2/g 
Stability and Storage Conditions: Magnesium stearate is stable and should be stored in a 
well-closed container in a cool, dry place. 
Pharmaceutical Application 
 Magnesium stearate is widely used in cosmetics, food and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
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Non-proprietary names 
Synonyms 
Chemical name and 
molecular weight 
Empirical Formula and 
Molecular Weight 
Structural formula 
Functional Category 
 
Applications in 
Pharmaceutical 
Formulation 
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4.5.Mannitol 
BP: Mannitol 
JP: D-Mannitol 
PhEur: Mannitol 
USP: Mannitol 
Cordycepic acid; C*PharmMannidex; E421; Emprove; 
mannasugar; D-mannite; mannite; mannitolum; 
D-Mannitol [69-65-8] 
C6H14O6 182.17 
Diluent; plasticizer; sweetening agent; tablet and capsule 
diluent; therapeutic agent; tonicity agent. 
Mannitol is widely used in pharmaceutical formulations and 
foodproducts. In pharmaceutical preparations it is primarily 
used as a diluent (10–90% w/w) in tablet formulations, where it 
is of particular value since it is not hygroscopic and may thus be 
used with moisture-sensitive active ingredients. Mannitol may 
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be used in direct-compression tablet applications,for which the 
granular and spray-dried forms are available, or in wet 
granulations. Granulations containing mannitol have the 
advantage of being dried easily. Specific tablet applications 
include antacid preparations, glyceryltrinitrate tablets, and 
vitamin preparations. Mannitol is commonly used as an 
excipient in the manufacture of chewable tablet formulations 
because of its negative heat of solution, sweetness, and 
‘mouthfeel’. 
Description 
 
Mannitol is D-mannitol. It is a hexahydric alcohol related to 
mannose and is isomeric with sorbitol. Mannitol occurs as a 
white, odorless, crystalline powder, or freeflowing granules. It 
has a sweet taste, as sweet as glucose and half as sweet as 
sucrose, and imparts a cooling sensation in the mouth. 
Microscopically, it appears as ortho rhombic needles when 
crystallized from alcohol. Mannitol shows polymorphism. 
Stability and Storage 
Conditions 
 
Mannitol is stable in the dry state and in aqueous solutions. 
Solutions may be sterilized by filtration or by autoclaving and if 
necessary may be autoclaved repeatedly with no adverse 
physical or chemical effects. In solution, mannitol is not 
attacked by cold,dilute acids or alkalisor by atmospheric oxygen 
in the absence ofcatalysts. Mannitol does not undergo Maillard 
reactions.The bulk material should be stored in a well-closed 
container in acool, dry place. 
Incompatibilities Mannitol solutions, 20% w/v or stronger, may be salted out 
bypotassium chloride or sodium chloride. Precipitation has been 
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reported to occur when a 25% w/v mannitol solution was 
allowed to contact plastic. Sodium cephapirin at 2 mg/mL and 
30 mg/Ml concentration is incompatible with 20% w/v aqueous 
mannitol solution. Mannitol is incompatible with xylitol 
infusion and mayform complexes with some metals such as 
aluminum, copper, andiron. Reducing sugar impurities in 
mannitol have been implicated inthe oxidative degradation of a 
peptide in a lyophilized formation.Mannitol was found to 
reduce the oral bioavailability ofcimetidine compared to 
sucrose. 
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4.6.Aspertame 
 Nonproprietary Names 
  BP: Aspartame 
  PhEur: Aspartame 
  USP-NF: Aspartame 
Synonyms : 
(3S)-3-Amino-4-[[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-4-oxobutanoic acid; 3-
amino-N-(a-carboxyphenethyl)succinamic acid N-methyl ester; 3-amino-N-(a-
methoxycarbonylphenethyl)-succinamic acid; APM; aspartamum; aspartyl phenylamine 
methyl ester;Canderel; E951; Equal; methyl N-L-a-aspartyl-L-
phenylalaninate;NatraTaste;NutraSweet;Pal Sweet;Pal Sweet Diet;Sanecta;SC-18862;Tri-
Sweet. 
Chemical Name and CAS Registry Number : N-L-a-Aspartyl-L-phenylalanine 1-methyl 
ester [22839-47-0] 
Empirical Formula and Molecular Weight : C14H18N2O5 294.30 
Structural Formula 
Functional Category : Sweetening agent. 
Applications in Pharmaceutical Formulation or Technology : Aspartame is used as an 
intense sweetening agent in beverage products, food products, and table-top sweeteners, and 
in pharmaceutical preparations including tablets, powder mixes, and vitamin preparations.  
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It enhances flavor systems and can be used to mask some unpleasant taste characteristics; 
the approximate sweetening power is 180–200 times that of sucrose. 
Unlike some other intense sweeteners, aspartame is metabolized in the body and 
consequently has some nutritive value: 1g provides approximately 17kJ (4kcal). However, 
in practice, the small quantity of aspartame consumed provides a minimal nutritive effect. 
 Description : Aspartame occurs as an off white, almost odorless crystalline powder with 
an intensely sweet taste  
Incompatibilities 
Differential scanning calorimetry experiments with some directly compressible tablet 
excipients suggests that aspartame is incompatible with dibasic calcium phosphate and also 
with the lubricant magnesium stearate. Reactions between aspartame and sugar alcohols are 
also known. 
 Method of Manufacture 
Aspartame is produced by coupling togetherL-phenylalanine (orLphenylalanine methyl 
ester) andL-aspartic acid, either chemically or enzymatically. The former procedure yields 
both the sweet aaspartame and nonsweetb-aspartame from which thea-aspartame has to be 
separated and purified. The enzymatic process yields only 
a-aspartame. 
Stability and Storage Conditions : Aspartame is stable in dry conditions. In the presence 
of moisture, hydrolysis occurs to form the degradation productsL-aspartyl-Lphenylalanine 
and 3-benzyl-6-carboxymethyl-2,5-diketopiperazine with a resulting loss of sweetness. A 
third-degradation product is also known, b-L-aspartyl-L-phenylalanine methyl ester. For the 
stability profile at 258C in aqueous buffers. Stability in aqueous solutions has been 
enhanced by the addition of cyclodextrins, and by the addition of polyethylene glycol 400 at 
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pH 2. However, at pH 3.5–4.5 stability is not enhanced by the replacement of water with 
organic solvents. 
Methodolgy 
Pre-formulation studies 
Identification of Drug1,37:-                                          
Organoleptic Properties: 
The colour, odour  and  taste of the drug were recorded using descriptive terminology. 
Melting Point: 
Capillary tube is used to determine the Melting point. 
Solubility Study: 
It is important to know about solubility characteristic of a drug in aqueous 
system. Since they must possess some limited aqueous solubility to elicit a therapeutic 
response.The solubility of drug was recorded by using various descriptive 
terminology specified in Indian Pharmacopoeia, 2007. 
UV Spectrophotometric Study:  
The absorption maximum of the test solution was observed between 200-400 
nm region by using UV-Visible Spectrophotometer. 
Compatibility study: 
          A successful formulation of a stable and effective solid dosage form depends on 
careful selection of the excipients that are added to facilitate administration, promote 
the consistent release and bioavailability of the drug and protect it from degradation. 
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If the excipients are new and have not been used in formulations containing the active 
substance, the compatibility studies are of paramount importance. 
FT-IR: 
Compatibility of the Drug with the excipients was determined by subjecting 
the physical mixture of the drug and the polymers of the main formulation to infrared 
absorption spectral analysis. Any changes in chemical composition of the drug after 
combining it with the polymers were investigated with I.R. spectral analysis. 
          Fig : 5  Schematic representation of compatibility studies 
 
Procedure: 
                Weighed amount of drug (3mg) was mixed with 100mg of potassium 
bromide (dried at 40-50oC). The mixture was taken and compressed under 10-ton 
pressure in a hydraulic press to form a transparent pellet. The pellet was scanned by 
IR spectrophotometer. 
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Drug–Polymer Interaction/Compatibility study using FTIR  
Fourier Transfer Infrared Spectroscopy 
IR has been the method of choice to probe the nature and extent of 
interaction in polymer blends. IR was used in the study because mixing of the two 
components at molecular level will cause changes in oscillating dipoles of the 
molecules. If the drug and polymer interact then functional groups in FTIR spectra 
will show band shift and broadening compared to that of pure compounds. 
Method 
Potassium Bromide disc containing drug, polymer and their physical 
mixture were prepared to record the spectrum by using Shimadzu 8400S FTIR. 
Standard Calibration Curve of Ambroxol HCl 
Ambroxol Hclwas quantitatively analyzed by various techniques. In the 
present study, Ambroxol Hcl was estimated by UV spectrophotometry method.  
 Determination of λmax for Ambroxol Hcl 
Two different stock solutions of drug sample were prepared by dissolving 
100.0 mg of drug in 100.0 ml of Phosphate buffer were further diluted and analyzed 
spectrophotometrically to determine λmax. 
Observation:  
The λmax was found to be 246 nm. 
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Preparation of standard calibration curve of Ambroxol Hcl In 0.1 N HCl 
A. Preparation of Phosphate buffer of 6.8 pH which is prepared by preparing stock 
solutions of 27.218 g of Potassium di hydrogen Phosphate in 1000ml and 0.2M 
NaOH i.e 8 gms of NaOH in 1000ml and adding 250ml of potassium di hydrogen 
Phosphate and 112 ml of sodium hydroxide stock solution and make up to 1000ml. 
B. Preparation of dilutions for standard curve: Stock solution was prepared by 
dissolving 100.0 mg of Ambroxol Hcl in 100.0 ml of Phosphate buffer 
solutions, which was further diluted to give the solutions of concentration 2, 4, 
6, 8 and 10 µg/ml respectively. Absorbance of these solutions were measured 
on UV spectrophotometer at 246 nm and plotted against the concentration to 
give the standard curve.  
Evaluation of Mixed Blend38:- 
Bulk Density: 
An accurately weighed powdered blend from each formula is  introduced in to 
a measuring cylinder was shaken to remove any agglomerates. The volume occupied 
by the powder was measured which results in determining bulk volume bulk volume. 
It is  determined using the following formula. 
Loose bulk density =     Total weight of powder   
                                   Total volume of powder  
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Tapped bulk density (TBD): 
An accurately weighed powdered blend from each formula is introduced in to 
a measuring cylinder was shaken to remove any agglomerates.The measuring cylinder 
was tapped until no change in volume was noted which give the tapped volume. It is 
determined by using the following formula. 
 
Tapped bulk density =    Total weight of powder 
                    Total volume of tapped powder 
Hausner’s Ratio: 
It determined by using following formula: 
Hausner’s Ratio       =                Tapped bulk density 
                                                    Loose bulk density 
A hausner ratio less than 1.25 shows good flow while greater than 1.5 shows poor 
flow. 
Carr’s compressibility index 
It is a simple index that can be determined on little quantities of powder. The 
compressibility index of the formulation were determined by using following Carr’s 
compressibility index equation. 
Carr’s Compressibility Index (%) = Tapped bulk density- bulk density x100 
                                                             Tapped bulk density  
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Relationship between % compressibility and flowability is shown in the following 
table. 
Table 5: Standard values of Carr’s index 
Carr’s Index Type of flow 
5-15 Excellent 
12-16 Good 
18-21 Fair to passable 
23-35 Poor 
33-38 Very poor 
>40 Extremely poor 
 
Angle of Repose: 
It is determined by using the funnel method. The accurately weighed powder 
is taken in a funnel. The height of the funnel is adjusted in such a way that the tip of 
the funnel just touched the apex of the heap of the powder. The powder was allowed 
to flow through the funnel freely onto the surface. The diameter of the powder cone 
was measured to determine the angle of repose. 
It was calculated using the following equation. 
 
Where ‘h’ and ‘r’ are the height and radius respectively of the powder cone 
( )tan rh=θ
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                             Table 6: Standard values of angle of repose 
Flowability Angle of repose 
Excellent <25 
Good 25-30 
Passable 30-40 
Poor >40 
 
Method of manufacturing dispersible tablets 
Direct Compression Method  
 The Ambroxol Hcl dispersible tablets were prepared by using direct 
compression method with 9.5mm oval shapes punches  and  break line on one side of 
the tablet. The flow chart for direct compression method is given below in following 
representation. 
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Flow chart for Ambroxol Hcl dispersible tablets by using direct compression 
method 
                                                         Weighing  
              ↓ 
         Sifting  
              ↓ 
         Blending  
              ↓ 
       Lubrication 
              ↓ 
                                                  Tablet Compression 
 
Manufacturing Process 
Environment Condition   :  Room Temperature (250C), RH – 65% 
Manufacturing Characteristics   :  machine: Remek – Total 16 stations   
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Formulation of dispersible tablets ofAmbroxol HCl  by using natural gums 
Karaya gum and Guar gums as super disintegrants. 
 Method: Direct Compression Method  Preparation of Ambroxol hcl (F1- F6) by 
using direct compression method: Composition of  Ambroxol Hcl (F1 – F6): 
Table No: 7 Composition of  Oral disintegrating tablets of Ambroxol HCl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Ingredients (mg) F1 F2 F3 F4 F5 F6 
1 Ambroxol HCl 100 100 100 100 100 100 
2 Guar gum 6 10 18 - - - 
3 Karaya gum - - - 6 10 18 
4 
Microcrystalline 
cellulose 
50 50 50 50 50 50 
5 Mannitol 30 26 18 30 26 18 
6 Aspartame 10 10 10 10 10 10 
7 Magnesium stearate 4 4 4 4 4 4 
 TOTAL (mg) 200 200 200 200 200 200 
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Procedure: 
 Ingredients such as Ambroxol Hcl was sifted through 24 mesh, 
Microcrystalline cellulose was sifted through 40 mesh & ingredients such as Guar 
gum, Karaya gum, mannitol and aspartame, magnesium stearate, talc were passed 
through 60 mesh. The above ingredients were mixed in double cone blender for 25 
mins and lubricants were added to the above ingredients. The lubricated blend was 
compressed by using oval shaped  9.5 punches.  
Evaluation of Ambroxol Hcl dispersible tablets 
Physico-Chemical Properties of Tablets38: 
Hardness:  
  The hardness of tablets was determined by using Monsanto Hardness 
tester and it is expressed in Kg/cm2. The whole experiment was performed in 
triplicate 
Friability:                                                                       
          The friability of the tablet was determined by using Roche friabilator.It 
is expressed in percentage.Twenty tablets are initially weighed  W1 and transferred 
into the friabilator. The friabilator was operated at 25 rpm for 4 minutes.The tablets 
were weighed again (W2). The percentage of friability was calculated by using 
following formula. 
% Friability =      Initial weight - Final weight x 100 
                                            Initial weight 
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Weight variation:                                                
  20 tablets were selected randomly and weighed accurately. The weight 
divided by 20 provides an average weight of tablets. Not more than two of the 
individual weight deviates from the average weight by 10 % and none should deviate 
by more than double that percentage. Standard deviation and average weight were 
calculated 
Table 8: Specifications of % Weight Variation Allowed in Tablets                                                                              
as per Indian Pharmacopoeia 
 
 
 
 
 
 
 
 
 
 
 
 
Average weight of tablets (mg) 
Maximum percent  
difference allowed 
80 or less 10 
More than80 but less than 250 7.5 
250 or more 5 
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Uniformity of Content:                                       
The drug content in each formulation was determined by mixing 10 tablets and 
powder equivalent to 10 mg was added in 100ml of pH 6.8 phosphate buffer followed 
by stirring for 10 minutes. The solution was filtered through a 0.45µ filter paper, 
diluted suitably and the absorbance of resultant solution was measured by using UV-
Visible spectrophotometer at 246nm. 
Disintegration Test: 
 The test was carried out as per USP- 2008. 
One tablet was placed in six tubes of the basket. Phosphate buffer of pH 6.8 is 
used as the disintegration medium.The temperature of the liquid was maintained at 
370 c ± 20 c. If 1 or 2 tablets fail to disintegrate completely, repeat the test on 12 
additional tablets, not less than 16 of total of 18 tablets should disintegrate 
completely. 
 Wetting time: 
 A piece of filter paper folded twice and placed in a small petri dish  containing 
5ml of distilled water. The tablet was placed on the paper, and the time for complete 
wetting of the tablet was measured in seconds. The wetted tablet was then weighed. 
Wetting time, S, was determined by using following formula. 
S = 10× Wb-Wa/Wb 
Where,   Wa  –  weight of the tablet before water absorption. 
             Wb  –  weight of the tablet after water absorption. 
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 In- Vitro Drug Release Study39:-                            
   There are no standard methods yet developed for determining the in 
vitro drug release for dispersible tablets. The release rate of dispersible tablets of 
Ambroxol Hcl was carried out using rotating paddle apparatus (USP Type II). The 
dissolution medium consisted of 900 ml of phosphate buffer (pH 6.8). The release 
study was performed at 37 0C ± 0.5 0C with a rotation speed of 50 rpm. The 5ml of 
sample was withdrawn at time interval of 5, 10, 15,20minutes up to 30 min and 
replaced with 5 ml of dissolution medium the amount of Ambroxol Hcl released was 
determined by UV Spectrophotometer at 246 nm. 
Table 9: Parameters were used for the dissolution study 
Apparatus 
USP Dissolution  
apparatus (Type II) 
Dissolution medium Phosphate buffer (pH 6.8) 
Temperature 37±0.5 °C 
Volume 900 ml 
Speed 50 rpm 
Sample withdrawn 5 ml 
Running Time 30 min 
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Kinetics of In-vitro Drug Release40:           
  To study the release kinetics of in-vitro drug release, data was applied 
to kinetic models such as zero order, first order, Higuchi and Korsmeyer- Peppas. 
Zero order: 
Drug dissolution from dosage forms that do not disaggregate and release the 
drug slowly can be represented by the equation: 
Q0 n Qt = K0t 
Rearrangement of equation 
Qt = Q0 + K0t 
 Where, 
  Qt -  is the amount of drug dissolved in time t, 
  Q0 -  is the initial amount of drug in the solution (most times, Q0 = 0)  
K0 - is the zero order release constant expressed in units of concentration/time.  
To study the release kinetics, data obtained from in vitro drug release studies were 
plotted as cumulative amount of drug released versus time.  
Application:  
This relationship can be used to describe the drug dissolution of several types 
of modified release pharmaceutical dosage forms, as in the case of some transdermal 
systems, as well as matrix tablets with low soluble drugs in coated forms, osmotic 
systems, etc. 
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First order: 
This model has also been used to describe absorption and/or elimination of 
some drugs, although it is difficult to conceptualize this mechanism on a theoretical 
basis. The release of the drug which followed first order kinetics can be expressed by 
the equation 
 
Where,  
K -  is first order rate constant expressed in units of time-1. 
log C = log C0 n Kt / 2.303 
where, 
C0 - is the initial concentration of drug     
           K - is the first order constant 
           t - is the time in hrs.  
The data obtained are plotted as log cumulative percentage of drug remaining vs. time 
which would yield a straight line with a slope of -K/2.303. 
Application:  
This relationship can be used to describe the drug dissolution in 
pharmaceutical dosage forms such as those containing water-soluble drugs in porous 
matrices. 
Chapter - 4                              MATERIALS AND METHODS 
 
Department of Pharmaceutics                93              JKKMMRF College of Pharmacy 
 
Higuchi: 
The first example of a mathematical model aimed to describe drug release 
from a matrix system was proposed by Huguchi in 1961. Initially conceived for planar 
systems, it was then extended to different geometrics and porous systems. This model 
is based on the hypotheses that  
Initial drug concentration in the matrix is much higher than drug solubility. 
 Drug diffusion takes place only in one dimension (edge effect must be negligible). 
 Drug particles are much smaller than system thickness;  
 Matrix swelling and dissolution are negligible.  
 Drug diffusivity is constant. 
 Perfect sink conditions are always attained in the release environment. Accordingly, 
model expression is given by the equation: 
 
Where,  
Q- is the amount of drug released in time t per unit area A, 
C -is the drug initial concentration,  
Cs- is the drug solubility in the matrix media 
D- is the diffusivity of the drug molecules (diffusion coefficient) in the matrix 
substance.  
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This relation is valid during all the time, except when the total depletion of the 
drug in the therapeutic system is achieved. To study the dissolution from a planar 
heterogeneous matrix system, where the drug concentration in the matrix is lower 
than its solubility and the release occurs through pores in the matrix, the expression is 
given by equation. 
 
Where,  
D- is the diffusion coefficient of the drug molecule in the solvent, 
 δ -is the porosity of the matrix, 
τ -is the tortuisity of the matrix. 
Q, A, Cs and t have the meaning assigned above.  
Tortuisity is defined as the dimensions of radius and branching of the pores and canals 
in the matrix. In a general way it is possible to simplify the Higuchi model  as 
generally known as the simplified Higuchi model.  
 
Where,  
KH is the Higuchi dissolution constant. The data obtained were plotted as cumulative 
percentage drug release versus square root of time. 
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Application:  
This relationship can be used to describe the drug dissolution from several 
types of modified release pharmaceutical dosage forms, as in the case of some 
transdermal systems and matrix tablets with water soluble drugs. 
Korsmeyer Peppas: 
Korsmeyer et al. (1983) derived a simple relationshipwhich described drug 
release from a polymeric system equation. To find out the mechanism of drug release, 
first 60% drug release data were fitted in Korsmeyer Peppas model. 
 
Where,  
Mt / M∞ - is a fraction of drug released at time t, 
 k-  is the release rate constant and n is the release exponent.  
The n value is used to characterize different release for cylindrical shaped matrices.In 
this model, the value of n characterizes the release mechanism of drug as described 
should only be used. To study the release kinetics, data obtained from in vitro drug 
release studies were plotted as log cumulative percentage drug release versus log 
time. 
The value of n indicates the drug release mechanism related to the geometrical 
shape of the delivery system, if the exponent n = 0.5, then the drug release mechanism 
is Fickian diffusion. If n < 0.5 the mechanism is quasi-Fickian diffusion, and  0.5 < n 
< 1.0, then it is non-Fickian or anomalous diffusion and when n = 1.0 mechanism is 
non Fickian case II diffusion, n> 1.0 mechanism is non Fickian super case II. 
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Stability Study41:  
Stability Studies:[29] 
Introduction 
The purpose of stability testing is to provide evidence on how the quality of an active 
substance or pharmaceutical product varies with time under the influence of a variety 
of environmental factors such as temperature, humidity, and light. In addition, 
product-related factors influence the stability, e.g. the chemical and physical 
properties of the active substance and the pharmaceutical excipients, the dosage form 
and its composition, the manufacturing process, the nature of the container-closure 
system, and the properties of the packaging materials. Also, the stability of excipients 
that may contain or form reactive degradation products, have to be considered. 
Table- 10: Objectives of Stability Testing: 
OBJECTIVE TYPE OF STUDY USE 
To select adequate (from the 
viewpoint of stability) 
formulations and container-
closure systems 
Accelerated 
Development of the 
product 
To determine shelf-life and 
storage conditions 
Accelerated and 
real-time 
Development of the 
product and of the 
registration dossier 
To substantiate the claimed shelf- Real-time Registration dossier 
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life 
To verify that no changes have 
been introduced in the 
formulation or manufacturing 
process that can adversely affect 
the stability of the product 
Accelerated and 
real- time 
Qeleuality assurance in 
general, including quality 
control. 
 
Climatic Zones and Conditions 
WHO has issued guidelines, where it is stated that the world is divided into four zones 
based on the prevailing annual climatic conditions for the purpose of stability testing. 
Zone I: temperate 
Zone II: subtropical with possible high humidity 
Zone III: hot/dry 
Zone IV: hot/humid 
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Table-11: Mean climatic conditions: measured data in the open air and in the 
storage room 
Climatic 
Zone 
Measured data in the 
Open Air 
Measured data in storage 
room 
oC %RH oC %RH 
 
I 
II 
III 
IV 
 
10.9 
17.0 
24.4 
26.5 
 
75 
70 
39 
77 
 
18.7 
21.1 
26.0 
28.4 
 
45 
52 
54 
70 
 
So for example if a manufacturer plans to sell his products in zone-III he/she 
should do real time studies at 30oC and 35%RH.If a manufacturer wants to apply for 
the registration of a new drug, i.e. if he is applying for a (1) Investigative New Drug 
Application (IND) or (2) New Drug Application (NDA) or (3) Abbreviated New Drug 
Application (ANDA) then he has to assure the FDA regarding the drug’s/drug 
product’s safety, quality and efficacy. For this he has to carry out stability tests and 
submit stability data. How he should do this is specified by Q1A (R2). 
  
Chapter - 4                              MATERIALS AND METHODS 
 
Department of Pharmaceutics                99              JKKMMRF College of Pharmacy 
 
Selection of Batches 
Data from formal stability studies should be provided on at least three primary 
batches of the drug substance. These batches should be made to a minimum of pilot 
scale by the same synthetic route as that of the production batches. 
Specifications which include testing methods and acceptance criteria should be fixed. 
Testing frequency in Months 
Long term:    0, 3, 6, 9, 12, 18, 24 
Accelerated storage:   0, 3, 6 
Storage conditions recommended 
Table-12 : Testing frequency for different storage conditions 
Study Storage condition Minimum time 
period covered 
by data at 
submission 
Long term* 250C + 20C/60% RH + 5% RH or 
300C + 20C/65% RH + 5% RH 
12 months 
Intermediate** 300C + 20C/65% RH + 5% RH 6 months 
Accelerated 400C + 20C/75% RH + 5% RH 6 months 
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* It is up to the applicant to decide whether long term stability studies are performed 
at 25 + 2oC/60% RH + 5% RH or 30 0C + 2oC/65% RH + 5% RH.  
** If 30oC + 2oC/65% RH + 5% RH is the long-term condition, there is no 
intermediate condition.  
If long-term studies are conducted at 25oC+ 2oC/60% RH + 5% RH and “significant 
change” occurs at any time during 6 months’ testing at the accelerated storage 
condition, additional testing at the intermediate storage condition should be conducted 
and evaluated against significant change criteria (ICH, 2003) 
“Significant change” for a drug substance is defined as failure to meet is specification. 
Table -13 : Drug substances intended for storage in a refrigerator 
  Study Storage condition 
Minimum time period 
covered by data at 
submission 
Long term 50C + 30C 12 months 
Accelerated 250C + 20C/60% RH + 5% RH 6 months 
 
Table-14 : Drug substances intended for storage in a freezer 
Study Storage condition 
Minimum time period covered by data at 
submission 
Long term 200C + 50C 12 months 
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Stability Testing for Established Drug Substances 
WHO has issued guidelines for stability testing of pharmaceutical products 
containing well established drug substances in conventional dosage form. The 
stability of finished pharmaceutical products depends on environmental factors and on 
product related factors. So stability considerations should be given, the highest 
priority in the design and formulation of a product. The shelf life should be 
established with due regard to the climatic zones. To ensure both patient safety and 
the rational management of drug supplies, it is important that the expiry date and 
storage conditions are properly indicated on the label. 
Accelerated stability testing 
These are the studies designed to increase the rate of chemical degradation and 
physical change of a drug by using exaggerated storage conditions as part of the 
formal stability testing programme. The data thus obtained, in addition to those 
derived from real – time stability studies, may be used to assess longer – term 
chemical effects under non-accelerated conditions and to evaluate the impact of short-
term excursions outside the label storage conditions, as might occur during shipping. 
The results of accelerated testing studies are not always predictive of physical 
changes. These are also known as stress testing studies. 
Expiry date 
The date given on the individual container of a drug product up to and 
including which the product is expected to remain within specifications if stored 
correctly. It is established for each batch by adding the shelf-life period to the date of 
manufacture. 
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Real time (Long term) stability studies: 
Experiments on the physical, chemical, biological, biopharmaceutical and 
microbiological characteristics of a drug, during and beyond the expected shelf life 
and storage periods of samples under the storage conditions expected in the intended 
market. The results are used to establish the shelf life, to confirm the projected shelf 
life and to recommend storage conditions. 
Stability testing is an integral part of formulation development. It generates 
information on which to base proposals for the shelf lives of drug substances and 
products and their recommended storage conditions. Stability data also are a part of 
the dossier submission to regulatory agencies for licensing approval. 
Stability testing ensures that a drug substance will be safe and effective 
throughout the shelf life of the product. However, meeting the potency and purity 
profiles established in the compendia can be challenging as pharmaceutical products 
become increasingly complex and diverse. 
The optimized formulation F3 packed in PVC blister pack then, they were 
stored at three different temperatures 40C±20C, 270C±20C and 450C±20C for 45 days 
at RH 75±5%. At 15 days intervals, the tablets were evaluated for their physical 
appearance, drug content and drug excipients compatibility at specified intervals of 
time. 
 
Chapter -5                                                                      Results and Discussion 
 
Department of Pharmaceutics            103        JKKMMRF college of harmacy 
 
 5. RESULTS AND DISCUSSION 
5.1 Identification of Drug: 
Organoleptic properties: 
Colour: White or slightly yellow. 
   Odour: Odourless. 
Taste: Tasteless. 
   Nature: crystalline powder. 
5.2Melting point: 
                                     232.7oc 
5.3 Solubility study: 
Sparingly soluble in water,Soluble in methyl alcohol,Practcally iinsoluble in 
methylene chloride 
5.4 standard calibration curve  of  Ambroxol Hcl 
 Serial of dilutions are made from standard working solution with distilled 
water to get concentration from 20 to 100 microgram ⁄ ml and the absorbance was 
measured at 246nm. 
Table No: 15 Standard Calibration curve of Ambroxol Hydrochloride 
S.No Concentration (mcg/ml) Absorbance 
1 20 0.114 
2 40 0.226 
3 60 0.352 
4 80 0.470 
5 100 0.582 
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Graph 2: lambda max of Ambroxol Hydrochloride 
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Graph 1:Standard graph of Ambroxol Hcl
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Table: IR characteristic functional groups of pure drug and Drug polymer 
mixture:  
Functional groups Drug Drug + polymer 
NH2 Stretch 3396.76 3396.76 
N-H Stretch 3281.99 3281.99 
CH2 Stretch 2929.00 2934.79 
OH Stretch 3196.10 3194.23 
CH=CH stretch 3055.33 3054.31 
CN Stretch 1457.27 1457.27 
 
IR spectra of pure Ambroxol HCl showed the major bands .From the above 
table and figures 6-10, it can be seen that, the major functional group peaks observed 
in spectras of Drug with all the polymers remains unchanged as compared with 
spectra of Ambroxol Hcl. So from the above IR spectra it can be observed that there is 
no interaction between Ambroxol Hcl and Polymers used in the formulations. 
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5.6 Micromeritic properties to the Ambroxol oro dispersible tablets: 
 The results of the Micromeritic properties of the granules are presented in 
table No: 16. 
Table No: 16 Micromeritic properties of Ambroxol HCl Dispersible tablets 
Form. 
No 
Angle of 
repose 
(θ°) 
Bulk 
density 
(gm/cm3) 
Tapped 
density 
(gm/cm3) 
Compressi-
bility Index 
(%) 
Hausner 
Ratio 
F1 22.33 0.425 0.464 8.60 1.094 
F2 22.29 0.416 0.459 9.36 1.103 
F3 24.15 0.425 0.465 8.60 1.094 
F4 23.48 0.421 0.459 8.27 1.090 
F5 25.26 0.431 0.470 9.57 1.105 
F6 22.78 0.425 0.481 10.60 1.118 
 
The Bulk density of various powder mixed blends prepared with different 
superdisintegrants, was measured by graduated cylinder. The bulk density was found 
in the range 0.416– 0.431 kg/cm3. 
 The Tapped density of various powder mixed blends prepared with different 
superdisintegrants, was measured by graduated cylinder. The Tapped density was 
found in the range 0.459– 0.481 gm/cm3. 
 The Compressibility index of various powder mixed blends, prepared with 
different superdisintegrants, using bulk density and tapped density data, 
compressibility index was calculated. It was found in the range 8.27 – 10.60%. 
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 The Hausner’s ratio of various powder mixed blends, prepared with different 
superdisintegrants, using bulk density and tapped density data, Hausner’s ratio was 
calculated. It was found in the range 1.090 – 1.118. 
 Angle of repose ranged from 22.29-25.26. The flow properties of powder blend 
in all formulations exhibit good flow characteristics. 
5.7 Appearance of the tablet: 
 White colored, oval uncoated, molted tablet with plain surface on two side. 
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5.8  Physical Evaluation of the Ambroxol Hcl orodispersible tablets: 
 The result of the Physico-chemical properties of the prepared tablets was done 
as per the procedure and presented in the table no: 17. 
Table No -17 Physical Evaluation of the Ambroxol Hcl orodispersible tablets 
 
Evaluation of Ambroxol Hcl tablets: 
 Tablets were prepared using direct compression technique. Since the material 
was free flowing, tablets were obtained of uniform weight due to uniform die fill 
tablets were obtained in the range with acceptable weight variations as per 
pharmacopoeia specifications, less than 5%.  
 Tablets were evaluated by using Vernier calliper. The thickness of the tablets 
was found in the range 5.2 – 6.0 mm. Uniformity thickness was obtained due to 
uniform die fill. Tablets were evaluated by using Pfizer Hardness tester. Hardness of 
the tablets was found in the range 3.36 – 3.71 Kg/cm2. Uniform hardness was 
obtained due to equal compression force. 
For
m. 
No 
Weight 
variation
in mg 
Hardness 
(Kg/cm2) 
Friability 
(%) 
Disintegrat
ion time 
(min) 
Uniformity 
of 
     content 
Wetting 
time 
(sec) 
F1 202±7.5 3.50 0.293 1.20 Pass 54.55 
F2 200±7.5 3.48 0.293 1.09 Pass 55.86 
F3 201±7.5 3.42 0.291       1.04 Pass 54.47 
F4 205±7.5 3.58 0.428 1.25 Pass 56.37 
F5 199±7.5 3.68 0.426 1.19 Pass 59.35 
F6 200±7.5 3.71. 0.426 1.13 Pass 54.29 
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 Tablets were evaluated by using Roche Friabilator and friability of tablets was 
observed in the range 0.291 - 0.530. 
Tablets were evaluated for disintegration time in the IP disintegration 
apparatus. The disintegration time was found in the range 29 – 33 sec. 
The tablets are evaluated for the uniformity dispersion in which all the tablets 
were dispersed in few seconds in purified water and all the formulations were under 
the IP limits. 
 Tablets were evaluated for wetting time test. The wetting time was found in 
the range 54 – 59 sec. 
 Tablets are evaluated for the content uniformity test all the formulations are 
under the IP specifications 
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 5.9 Assay of prepared Ambroxol dispersible tablets: 
 The results of the assay of Ambroxol Hcl were done as per procedure and 
presented in the table no: 18. 
 
Table No: 18 Assay of prepared Ambroxol dispersible tablets 
Formulation 
 No 
 
Assay of Ambroxol 
Hcl  in % w/w 
F1 98.3 
F2 98.6 
F3 99.0 
F4 101.7 
F5 101.5 
F6 102.2 
 
  
Tablets were evaluated by using assay method. The drug was obtained in the 
acceptable limit. The drug content was found in the range 98.3 – 102.2%. 
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5.10 In–vitro drug release studies 
In–vitro drug release of Ambroxol HCl 
  
Table No: 19: In Vitro Dissolution Profile of Ambroxol Hcl dispersible tablets 
in pH6.8 Buffer Solution 
 
Time in 
mins 
F1 F2 F3 F4 F5 F6 
5 52.45 54.78 59.31 53.28 55.46 60.71 
10 66.44 67.80 72.54 70.78 69.80 79.88 
15 71.70 74.70 81.20 76.54 82.88 87.91 
20 81.89 83.10 89.13 83.72 91.43 92.14 
25 89.92 90.89 93.67 87.78 93.58 95.13 
30 90.71 94.97 98.21 91.12 94.45 97.99 
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Graph 3: In vitro Dissolution studies of Ambroxol Hcl dis integrating tablets 
formulations F1-F3 
 
Graph 4: In vitro Dissolution studies of Ambroxol Hcl dis integrating tablets 
formulations F4-F6 
 
Invitro drug release studies were conducted for the formulation using USP 
dissolution apparatus type-II (paddle), at 50 rpm. The percentage drug release at the 
end of 30 min was found in the range 90 – 98 %. 
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5.11 Kinetics study: 
Table 20: Dissolution Kinetics of optimized batch F6. 
TIME SQRT LOG TIME 
% DRUG 
REL 
LOG % D 
REL 
% D 
REM 
LOG % D 
REM 
0 0 #NUM! 0 #NUM! 100 2 
5 2.236068 0.69897 59.31 1.7731279 40.69 1.60948769 
10 3.162278 1 72.54 1.8605776 27.46 1.438700533 
15 3.872983 1.176091 81.2 1.909556 18.8 1.274157849 
20 4.472136 1.30103 89.13 1.9500239 10.87 1.036229544 
25 5 1.39794 93.67 1.9716005 6.33 0.80140371 
30 5.477226 1.477121 98.21 1.9921557 1.79 0.252853031 
                            
                          Graph 5: Percentage drug release profile 
 
                        Graph 6: Zero order plot 
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                                 Graph 7: First order drug profile 
 
                                         Graph 8: Higuchi’s plot 
 
 
                            Graph 9: Peppa’s korsemeyer’s plot 
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Discussion: 
 The release profile of the optimized formula F6 fitted best to Korsmeyer-
Peppas model with R2 value of 0.998. As the n value for the Korsmeyer-Peppas model 
was found to be less than 0.45, it follows Fickian transport. 
5.12 Stability studies: 
Table 21: Stability studies of Ambroxol Hcl oro dispersible tablets. 
Parameters After 15 days After 30 days After 45 days 
Physical appearance No change  No change  No change  
Weight variation (mg) 201±3.34 199±2.55 199±4.23 
Hardness (kg/cm2)  3.42±0.23 3.30±0.64  3.25±0.99  
Friability (%)  0.29±0.05 0.31±0.08  0.32±0.06  
Drug content (%/tablet)  99.00±0.34 98.81±0.29  98.01±0.87  
Wetting time (sec) 54.47±0.41 55.12±0.15 56.51±0.59 
Disintegration time (sec) 29.25±0.15 31.13±0.45 35.05±0.61 
Percentage drug release 98.21±0.96 95.36±0.19 85.15±0.15 
 
Discussion: 
  According to ICH guidelines, 45 days stability study at 40C ±20C, 270C 
±20C and 450C ±20C for 45 days at RH 75±5% of optimized formulation (F6) was 
carried out. It showed negligible change over time for parameters like appearance, 
drug content, dissolution and assay etc., No significant difference in the drug content 
between initial and formulations stored at 40C ±20C, 270C ±20C and 450C ±20C for 45 
days at RH 75±5% for 45 days. 
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6. SUMMARY AND CONCLUSION 
 The study was carried to formulate and evaluate dispersible tablet dosage form 
containing Ambroxol Hcl  as a mucolytic drug. 
 The present study is an attempt to select best possible combination of diluents 
and disintegrants to formulate dispersible tablet of Ambroxol Hcl which disintegrates 
within few minutes  there by reducing the time of onset of action. 
 Mannitol is selected as diluents, natural gums such as guar gum, Karaya gum 
were selected as super disintegrants. Microcrystalline cellulose was used in all 
formulations. Aspartame as a sweetening agent, Magnesium stearate as a Lubricant. 
Guar gum is used as the super disintegrant in the formulation F1 – F3 at the 
concentrations of the 6, 10, 18 % respectively. 
Karaya gum is used as the super disintegrant in the formulation F4 – F6 at the 
concentrations of 6, 10, 18 % respectively. 
Direct Compression method was used to formulate the tablets. 
All the formulations were showed the acceptable flow properties and the 
precompression parameters like Bulk density, Tapped density and Hausner ratio.  
The post compression parameters like Hardness, Friability, Disintegration time, 
Weight variation, wetting time, Dispersion time values were found to be within the IP 
limits. 
The percentage Drug content of all tablets was found to be between 98.3% - 102.2% 
of Ambroxol Hcl , which is within the  limit. 
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As the concentrations of  the guar gum increases in the formulations F1 – F3 the 
disintegration time found to be decreased and the disintegration time for these 
formulations were 1.20, 1.09, 1.04 seconds respectively and the percentage drug 
release was also found to be increased for these formulations as 90.71, 94.97, and 
98.21 % respectively. From the above results it was found that as the concentration of 
guar gum increased and microcrystalline cellulose decreases the disintegration and 
dissolution time was found to be improved, so considering the above results it was 
found that the F3 batch was found to be optimized batch and it pass all the 
preformulation parameters and evaluation results as per the IP limits 
From the data obtained, it is observed from the formulation containing Guar 
gum - 18mg, Micro crystalline cellulose - 50mg in Formulation F3, shows 
Disintegration time in 1.04 mins and the Percentage drug release is of 98.21 % at the 
end of 30 min which satisfied all the tablet evaluation parameters for dispersible 
tablet. Hence looking at all the satisfactory parameters F3 batch is selected as the 
optimized batch. 
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